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 RESUMO 
 
Introdução: Vários mecanismos têm sido sugeridos para explicar a elevada prevalência de 
doenças autoimunes (DAIs) na Imunodeficiência Comum Variável (ICV). Procurámos avaliar 
a prevalência de DAIs numa população com IDCV, caracterizar estes doentes e verificar se 
um defeito quantitativo na população T CD4+CD25high poderia estar associado à maior 
prevalência de autoimunidade na ICV. 
Métodos: Foram incluídos 47 doentes com ICV sob terapêutica substitutiva com 
imunoglobulina endovenosa (IGEV). Através de revisão dos processos clínicos e entrevista 
individual foram recolhidos dados clínicos e laboratoriais relativamente às manifestações de 
apresentação e evolução clínica, incluindo DAIs e níveis séricos de imunoglobulinas no 
diagnóstico de ICV. Em estudo transversal, foi quantificada IgG sérica e populações T, B e 
NK e células T CD4CD25 por citometria de fluxo em sangue total.  
Resultados: Foram diagnosticadas DAIs em 19 doentes (40,4%), sendo as citopénias 
autoimunes as mais frequentes. As DAIs foram diagnosticadas antes da ICV em 8 doentes, 
nenhum deles sob terapêutica imunossupressora no ano anterior ao diagnóstico de ICV. A 
idade média dos doentes com DAI era superior no momento do estudo, diagnóstico de ICV e 
no início da terapêutica com IGEV. Também apresentavam uma prevalência mais elevada de 
diarreia crónica não infecciosa e hiperplasia linfoide e IgG sérica mais elevada no 
diagnóstico. O estudo transversal não evidenciou diferenças significativas na IgG sérica pré-
infusional ou populações linfocitárias entre doentes com e sem DAI. As frequências de 
CD4+CD25high foram significativamente mais baixas em doentes com DAI comparados com 
doentes sem DAI e com controlos saudáveis e no conjunto dos doentes com ICV comparados 
com estes controlos.  
 I
 Conclusões: Estes resultados sugerem que a deficiência quantitativa de CD4+CD25high poderá 
contribuir para a elevada prevalência de DAIs na ICV. Uma avaliação longitudinal e mais 
detalhada da população T CD4+CD25high, incluindo marcadores fenotípicos adicionais e 
estudo funcional, contribuirão para clarificar esta questão. 
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 ABSTRACT 
 
Background: Several mechanisms have been proposed to explain the high incidence of 
autoimmune diseases (AID) in Common Variable Immunodeficiency (CVID). We aimed to 
evaluate AID frequency within a CVID population and to characterize patients with AID. We 
also investigated whether a quantitative defect in the immunoregulatory population 
CD4+CD25high could be associated with increased prevalence of autoimmunity in CVID.  
Methods: 47 patients with CVID on regular intravenous immunoglobulin substitution therapy 
were enrolled. Chart review and questionnaire-guided interview were used to collect clinical 
and laboratory data concerning presentation symptoms and clinical evolution, including AID. 
Serum immunoglobulins were quantified at diagnosis. A cross-sectional evaluation was 
performed before IVIG infusion, including serum IgG level, T, B and NK cell quantification 
by flow-cytometry in freshly whole blood. CD4+CD25+ cells were simultaneously quantified 
in whole blood by flow-cytometry and compared with age-matched healthy volunteers.  
Results: AIDs were diagnosed in 19 patients (40.4%) and autoimmune cytopenias were the 
most frequent. AID was diagnosed before CVID in eight patients, none on 
immunosuppressors in the year before CVID diagnosis. Patients with AID were older at the 
time of the present evaluation, at CVID diagnosis and at beginning of IVIG. They also 
exhibited higher prevalence of chronic non-infectious diarrhea and lymphoid hyperplasia and 
higher serum IgG at diagnosis. There were no significant differences in IgG pre-infusional 
levels and lymphocyte subpopulations between patients with and without AID. CD4+CD25high 
frequencies were significantly lower in patients with AID compared to those without AID and 
controls and in the whole group of CVID compared to controls.  
 III
 Conclusions: Our results suggest that CD4+CD25high deficiency may possibly contribute to 
the high incidence of AID in CVID. More detailed and longitudinal evaluation of 
CD4+CD25high T cells in larger cohorts, including the use of additional markers and 
suppressor cells function assessment, will help to clarify this issue. 
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PREÂMBULO 
 
A decisão de fazer o Mestrado em Imunologia Médica foi motivada essencialmente pela 
vontade de aprofundar o conhecimento na especialidade que escolhi para a prática clínica. 
Sendo parte integrante da formação e actividade em Imunoalergologia, as Imunodeficiências 
Primárias (IDPs) são, desde logo por motivos epidemiológicos, uma área com a qual 
contactamos com menor frequência, apesar de a prevalência global destas doenças se situar 
em 1: 20 000 nascimentos, se englobarmos todos os grupos de IDPs. A Imunodeficiência 
Comum Variável é a IDP sintomática mais frequente, encontrando-se actualmente em 
seguimento no Serviço de Imunoalergologia do HSM cerca de 35 doentes com ICV. São 
frequentemente casos complexos e absorventes, que se caracterizam por uma diversidade de 
patologias, com espectro de gravidade alargado. 
Do ponto de vista conceptual, as IDPs são extremamente instrutivas, constituindo verdadeiros 
modelos vivos que nos permitem compreender melhor o sistema imunitário. Para além do 
desafio que a sua complexidade de diagnóstico e as dificuldades na evolução clínica e 
terapêutica oferecem, o seguimento de doentes com IDPs torna-se hoje cada vez mais 
gratificante. O investimento da investigação nesta área tem contribuído para uma significativa 
melhoria da qualidade de vida dos doentes.  
Todos estes motivos em conjunto contribuíram para aumentar o meu interesse pelas IDPs e 
reforçam a pertinência da escolha deste tema, em particular da Imunodeficiência Comum 
Variável, para área de trabalho prático no Mestrado em Imunologia Médica. 
No decurso do Internato Complementar, estagiei durante o primeiro trimestre de 2004 no 
Hospital Vall d`Hebron, em Barcelona, centro de referência para crianças e adultos com IDPs 
da Catalunha. O dinamismo da orientação da Dra Teresa Español e a excelente recepção por 
parte dos colegas espanhóis permitiram rentabilizar de forma extraordinária aqueles 3 meses. 
Susana Lopes da Silva 
No Hospital Vall d´Hebron encontram-se em seguimento cerca de 15 crianças e 70 adultos 
com ICV, a maioria dos quais recorre àquela instituição para terapêutica substitutiva com 
IGEV. A possibilidade de acesso a uma população alargada e a disponibilidade do 
Laboratório de Imunologia, permitiram realizar o presente trabalho. Tendo colocado a 
hipótese original de um defeito quantitativo das células reguladoras CD4+CD25high  poder 
estar associado à elevada incidência de doenças autoimunes na ICV, sublinho e agradeço a 
disponibilidade e a coragem de toda a equipa para colaborar sem reservas com esta ideia.  
A realização do trabalho prático durante o tempo do estágio foi um objectivo extremamente 
ambicioso / exigente para este período, que no entanto contribuiu de forma decisiva para o seu 
sucesso. A avaliação clínica, baseada na revisão dos processos e entrevista clínica, foi 
obviamente afectada pelos condicionalismos da metodologia retrospectiva. O protocolo 
laboratorial foi desenhado em conjunto com a equipa do Laboratório de Imunologia, o qual 
suportou todos os encargos financeiros e num período record o integrou na sua rotina e nos 
demais trabalhos em curso. 
Obtiveram-se resultados significativos relativamente à hipótese colocada, original e integrada 
em linhas actuais de investigação em autoimunidade e imunodeficiências primárias humorais. 
Estes resultados, aliados ao facto de a autoimunidade constituir um problema 
simultaneamente frequente e intrigante para aqueles que na prática clínica e no laboratório 
lidam com doentes com ICV, motivaram a elaboração em inglês do artigo CD4+CD25high and 
Autoimmunity in Common Variable Immunodeficiency: searching new answers for an old 
question. 
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AID Autoimmune disease 
AIHA Autoimmune hemolytic anemia 
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BAFF-R B-cell activating factor receptor (BAFF-R) 
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CT Computed tomography 
CTLA-4 Cytotoxic T Lymphocyte associated-Antigen 4  
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Cy Cyclosporine  
DAI Doença autoimune 
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HCV Hepatitis C Virus 
HIV Human Immunodeficiency Virus 
ICOS Inducible Costimulator -  
ICV Imunodeficiência Comum Variável 
IDP Imunodeficiência Primária 
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Ig Immunoglobulin / Imunoglobulina 
ITP Immune thrombocytopenia  
IUIS International Union of Immunological Societies 
IVIG Intravenous immunoglobulin 
M Male 
NK Natural Killer 
NSAIDs Non-steroidal anti-inflammatory drugs 
OS Oral steroids  
PBMC Peripheral Blood Mononuclear Cell 
PCR Polymerase Chain Reaction 
PE Phycoerythrin 
PerCP Peridinin chlorophyll protein 
PID Primary immunodeficiency 
RA Rheumatoid arthritis  
SD Standard deviation 
SLE Systemic Lupus Erythematosus 
TACI Transmembrane activator and calcium-modulator and cyclophilin-ligand 
Interactor 
TRECs T-cell receptor-rearrangement excision circles 
T reg T regulatory / T reguladora 
WHO World Health Organization 
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RESUMO EXTENSO 
 
A Imunodeficiência Comum Variável (ICV) é a imunodeficiência primária (IDP) sintomática 
mais frequente, tendo uma prevalência estimada em 1 / 25 0001,2 entre a população ocidental. 
O diagnóstico definitivo de ICV baseia-se na diminuição de IgG, IgA e/ou IgM, pelo menos 2 
desvio-padrões em relação ao normal para a idade, associada à deficiência de produção de 
isohemaglutininas e/ou de anticorpos específicos e após exclusão de outras causas primárias 
ou secundárias de hipogamaglobulinémia3,4. O espectro clínico da ICV é extremamente amplo 
no tipo de manifestações clínicas e sua gravidade. Para além das infecções recorrentes, mais 
frequentemente respiratórias e digestivas, as doenças autoimunes5, a hiperplasia linfoide6, em 
alguns casos com padrão granulomatoso, e a incidência aumentada de neoplasias 
hematológicas7 são alguns dos problemas clínicos mais frequentes na ICV.  
A prevalência de doenças autoimunes (DAIs) na ICV tem sido estimada entre 21%8 a 
50%9,10,11, contrastando com os 5-7% calculados para a população geral12 e sugerindo a 
existência de defeitos imunológicos favorecedores da autoimunidade na ICV.  
Este intrigante aumento da incidência de DAIs mediadas por células e/ou por anticorpos, 
numa IDP predominantemente atribuída a défice de anticorpos constitui um paradoxo 
aparente e tem originado várias hipóteses visando a sua explicação13.  
A existência de uma predisposição genética para a autoimunidade em doentes com ICV é 
sugerida por estudos de linkage e tipagem HLA que têm demonstrado associações entre genes 
de susceptibilidade major para ICV e/ou défice de IgA e outros para DAIs9,14.  
Na ICV, como em outras IDPs, a infecção poderá constituir o elo entre a imunodeficiência e a 
autoimunidade15. A incapacidade de lidar com super-antigénios16 e de eliminação de 
antigénios externos, secundária aos múltiplos defeitos da imunidade inata e adquirida 
descritos na ICV, pode levar à formação de anticorpos contra tecidos lesados pelos agentes 
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infecciosos ou por uma resposta inflamatória exacerbada aos mesmos, a reactividade cruzada 
entre tecidos do doente e antigénios estranhos ou à deposição de complexos imunes.  
Entre os múltiplos defeitos identificados na diferenciação / função dos linfócitos B, salientam-
-se defeitos na maturação de células de memória CD19+CD27+ 10,17,18,19,20. Warnatz et al e Ko 
et al demonstraram que doentes com maior deficiência de células B de memória class-
switched têm maior prevalência de DAIs18,20. Contrariamente, Piqueras et al não confirmaram 
esta associação, mas verificaram maior prevalência de esplenomegália, proliferação linfoide e 
doença granulomatosa no grupo de doentes com maior deficiência na maturação de linfócitos 
B19. 
Múltiplos defeitos de imunidade celular estão também descritos na ICV, nomeadamente 
linfopénia T21, sobretudo CD4 naive22,23, para a qual podem contribuir a redução de 
progenitores mononucleares na medula óssea24, deficiência de timopoiese2,24,, deficiência de 
IL225 e IL726 e aumento da apoptose27,28,29. Outros defeitos funcionais na imunidade celular 
incluem ainda alterações na activação e proliferação T8,30 e na produção de citocinas, estando 
descrito neste contexto um desvio Th12 e diminuição de citocinas Th2, nomeadamente IL4, 
IL5 e IL1031, 32, 33, 34, 35.  
A falência de mecanismos de indução e/ou manutenção de tolerância central ou periférica 
pode também contribuir para o aumento da incidência de DAIs na ICV.  
As células T reguladoras, entre as quais as CD4+CD25high, estão envolvidas na manutenção de 
tolerância ao self, através da supressão activa da activação e expansão de células T auto-
reactivas existentes à periferia de todos os indivíduos saudáveis36. As células T reguladoras 
estão também envolvidas não só na supressão de reacções alérgicas e reacção enxerto vs 
hospedeiro após transplante, mas também da resposta a infecções e tumores37,38.  
Com este estudo pretendemos verificar se uma deficiência quantitativa de CD4+CD25high se 
poderia associar ao aumento da prevalência de DAI descrito na ICV, podendo este ser um 
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defeito universal ou definir um perfil particular de um subgrupo de doentes com expressão 
clínica / laboratorial de autoimunidade. Embora tivesse já sido anteriormente sugerida a 
existência de um compromisso funcional das células T supressoras na ICV e sua associação 
com o aumento de prevalência de DAIs14, a hipótese de um defeito quantitativo de 
CD4+CD25high nunca antes tinha sido testada. 
Sakagushi et al demonstraram que a depleção de células reguladoras CD4+CD25+ resulta no 
desenvolvimento de DAIs em ratinhos39. O mesmo grupo demonstrou em animais que uma 
população minor de células T CD4+CD25+ é crucial para o controlo de células T autoimunes 
in vitro40,41. Diversas AID foram induzidas em estirpes susceptíveis de ratinhos, em 
protocolos envolvendo remoção completa ou alteração do desenvolvimento das células T 
CD4+CD25+, nos quais a co-transferência de células T CD4+CD25+ evitava o 
desenvolvimento de DAIs38,41,42. Adicionalmente, os ratinhos com deficiência primária de 
CD25 demonstraram ser susceptíveis a autoimunidade grave que podia ser evitada pela 
inoculação de células T CD4+CD25+ de ratinhos singénicos43. No seu conjunto, estes dados 
sugerem que as células T CD4+ que expressam primariamente a cadeia α do receptor da IL2 
(CD25) desempenham um papel importante na patogénese das DAIs. 
Uma população com propriedades in vitro fenotípicas e funcionais idênticas foi 
posteriormente definida nos humanos, no sangue periférico, timo e sangue venoso umbilical 
de recém-nascidos saudáveis44,45,46,47,48. A capacidade supressora destas células foi 
preferencialmente associada às células T CD4 com maior intensidade de expressão de CD25 
(CD4+CD25high)44 e num estadio final de diferenciação, sendo maioritariamente 
CD4+CD25+CD45RA-CD45RO+ 44. A população total CD4+CD25+ contém uma proporção 
relativamente elevada de células T activadas, já que o CD25 é expresso transitoriamente à 
superfície de células T CD4+ não reguladoras após activação, não conferindo actividade 
supressora44.  
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Muitos trabalhos têm procurado clarificar o papel das células T CD4+CD25+ na patogénese 
das DAIs no ser humano. Defeitos quantitativos e / ou funcionais têm sido descritos em 
diversas DAIs, embora os resultados sejam escassos e discrepantes. Diferentes autores 
encontraram uma diminuição do número de células T CD4+CD25+ circulantes na diabetes 
insulino dependente49, hepatite autoimune50 e lúpus eritematoso sistémico51,52 e defeito 
funcional, mas não quantitativo, no síndrome poliglandular tipo II53, esclerose múltipla54 e 
diabetes autoimune55,56. Outros estudos não detectaram qualquer deficiência de CD4+CD25high 
na miastenia gravis57, esclerose múltipla58, diabetes insulino-dependente59 e síndrome de 
Sjögren60. Na artrite reumatoide foi encontrada maior quantidade de células T reguladoras, 
com actividade supressora mais intensa, no líquido sinovial de articulações inflamadas, em 
comparação com o sangue periférico dos mesmos doentes61,62, um fenómeno com fundamento 
possivelmente equiparável ao aumento de células reguladoras CD4+CD25+ verificado na 
mucosa intestinal de doentes com doença inflamatória intestinal61,62.  
No presente trabalho, foi estudada uma população de 47 doentes com ICV seguidos no 
Hospital Vall d´Hebron, em Barcelona, com os objectivos de avaliar a frequência de DAI 
nesta população, caracterizar os doentes com ICV e DAI e comparar o seu perfil clínico e 
imunológico com o de doentes sem DAI. Pretendemos ainda avaliar a frequência de 
CD4+CD25high em doentes com ICV e DAI em comparação com controlos saudáveis. 
A caracterização clínica foi realizada através da revisão do processo clínico hospitalar e 
entrevista guiada com cada doente. Foram colhidos dados relativos à ICV, nomeadamente 
idade e tipo de apresentação, evolução clínica, idade de diagnóstico e de início de terapêutica 
substitutiva com imunoglobulina endovenosa (IGEV), para além da evolução de eventuais 
DAIs, incluindo tipo de DAI, idade de diagnóstico e respectivo tratamento. Foram ainda 
recolhidos dados laboratoriais, nomeadamente doseamento de IgG, IgA, IgM, subclasses de 
IgG e produção de anticorpos específicos na altura do diagnóstico de ICV. Em paralelo, 
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realizou-se uma avaliação laboratorial transversal desta população, incluindo IgG pré–
infusional, hemograma e imunofenotipagem com quantificação por citometria de fluxo das 
populações B, NK, T CD4+, T CD8+ e expressão de HLA-DR nas duas últimas subpopulações 
T. Em paralelo, foi feita a avaliação quantitativa da percentagem de CD25high entre as células 
T CD4+, por citometria de fluxo em amostras de sangue total com tripla marcação CD4 / 
CD25 / CD45-RO, cujos resultados foram comparados com os obtidos numa população 
controlo de 29 saudáveis.  
Foram identificados 19 doentes (40,4%) com manifestações de DAI ao longo da sua evolução 
clínica. As DAIs detectadas foram Síndrome de Evans, trombocitopénia autoimune, anemia 
perniciosa, eritroblastopenia, artrite reumatoide, vitiligo, alopecia areata, psoríase, Síndrome 
de Sjögren, hepatite autoimune, doença de Crohn e hipotiroidismo primário. Cunninghan-
Rundles et al descreveram DAI em 52 / 248 doentes8, embora prevalências ainda mais altas 
tenham sido reportadas na literatura (28%63 a 50%10). Tal como em outras séries, as 
citopénias autoimunes foram as DAIs mais frequentemente diagnosticadas (6 / 47)10,64, 
seguidas da artrite reumatoide e anemia perniciosa (6,4%). 
Verificámos um predomínio não significativo do sexo feminino, tanto no conjunto de toda a 
população com ICV, como entre os doentes com DAIs. A idade de início dos sintomas foi 
muito variável, mas em média ligeiramente mais precoce que em outras séries (15,6 ± 14,7 
anos)8,9.  
As primeiras manifestações atribuíveis à imunodeficiência no grupo de doentes com DAI 
foram as infecções respiratórias recorrentes, seguidas da autoimunidade em oito doentes, 
nenhum deles sob terapêutica imunossupressora durante o ano que precedeu o diagnóstico de 
ICV. Apenas dois doentes estavam sob terapêutica imunossupressora (ciclosporina) aquando 
da realização da avaliação laboratorial transversal.  
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A idade média dos doentes com ICV e DAI era significativamente superior à dos doentes sem 
DAI, não só no momento da realização do estudo, como no aparecimento dos primeiros 
sintomas atribuíveis à ICV e no início da terapêutica com IGEV. Os doentes com DAI 
apresentavam demora média desde os primeiros sintomas até ao diagnóstico de ICV 
significativamente mais longa.  
Não se verificaram diferenças na idade de apresentação ou de diagnóstico de ICV quando 
comparados doentes que tiveram manifestações de DAI como primeiros sintomas com os 
restantes, com outros tipos de apresentação. No entanto, os doentes com DAI, mas em que 
esta não foi a primeira manifestação de ICV tiveram demora média significativamente mais 
longa desde a apresentação até ao diagnóstico de ICV do que doentes sem DAI. 
Verificámos que os doentes com DAI tinham mais frequentemente diarreia crónica não 
infecciosa e hiperplasia linfoide, sendo esta diferença significativa. As infecções respiratórias 
recorrentes e bronquiectasias, associadas frequentemente a tosse crónica e sinusite, e as 
gastrenterites infecciosas foram frequentes no conjunto de todos os doentes, no entanto sem 
diferença significativa entre os doentes com e sem DAI.  
Atendendo aos níveis de referência de imunoglobulinas séricas para cada idade, a IgA e IgG 
no diagnóstico estavam diminuídas em todos os doentes com DAI, encontrando-se a IgM 
dentro dos valores de referência em cinco destes doentes. A IgG sérica no diagnóstico era 
significativamente superior em doentes com DAI, particularmente nos que tinham esta forma 
de apresentação inicial, quando comparados com doentes sem DAI.  
Aquando da avaliação transversal todos os doentes estavam sob terapêutica com IGEV com 
doses e periodicidade muito variáveis (de 373 a 1360 mg/Kg/mês). A IgG pré-infusional, 
hemograma e as populações B, NK, T CD4+, T CD8+ não revelaram diferenças significativas 
entre os doentes com e sem DAI.  
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Os doentes com ICV e DAI apresentaram médias de frequências de células T CD4+CD25+ e 
de CD4+CD25high significativamente inferiores às dos doentes sem DAI e controlos saudáveis. 
O conjunto total de doentes com ICV apresentou também frequência média CD4+CD25high 
inferior quando comparada com a dos controlos, sendo esta diferença mais significativa no 
grupo dos doentes com DAI e mantendo significado estatístico após exclusão dos dois 
doentes sob terapêutica com ciclosporina.  
A percentagem de células CD25high entre as células T CD4+ foi extremamente variável nos 
doentes e nos controlos, salientando-se o facto de a média das frequências de CD4+CD25high 
obtida no grupo dos controlos saudáveis (1,25 ± 0,26 %) ter sido muito semelhante à obtida 
por Baecher-Allan et al no trabalho utilizado como referência metodológica para definição da 
população CD25high no presente estudo44. Naquele trabalho, as células CD4+CD25high foram 
estimadas em 1-2% da população T CD4+, sendo definidas por citometria de fluxo, com dupla 
marcação CD4 e CD25, como uma subpopulação que se destaca da população contendo 
CD4+CD25low e CD4+CD25-  44.  
Mais recentemente, diversos autores têm descrito outras formas de definir a mesma 
população52,55,56,59,60, alguns deles com maior objectividade, sendo outros omissos em relação 
à metodologia, incluindo critérios de definição de elevada expressão de CD2551,53,57, o que 
dificulta a comparação entre resultados. No nosso trabalho, tentámos minimizar a 
subjectividade do método escolhido através da quantificação de CD4+CD25high por um único 
investigador, sem acesso aos dados clínicos e aplicando os mesmos critérios em todos os 
doentes.   
Na nossa população, as células CD4+CD25high eram maioritariamente de memória CD45RO+, 
tanto nos doentes com ICV como nos controlos. Foi avaliada a expressão de HLA-DR nas 
células T CD4+ e T CD8+, não tendo sido encontradas diferenças nos valores absolutos ou 
percentagens de células T CD4+, T CD8+, CD4+HLADR+ ou CD8+HLADR+ entre doentes 
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com e sem DAI. Estes resultados e a ausência de correlação entre CD4+CD25highCD45RO+ e 
essas subpopulações sugerem que as diferenças encontradas nas frequências de CD4+CD25high 
não seriam apenas directamente dependentes de uma maior activação imunológica. 
Outros marcadores têm sido associados às células T reguladoras CD4+CD25+ T, incluindo 
CD152 (Cytotoxic T Lymphocyte associated-Antigen 4 - CTLA-4), GITR (Glucocorticoid-
Induced TNF-Receptor family-related gene), CD62L e o factor de transcrição FoxP3. Este 
último está descrito como essencial ao desenvolvimento e actividade supressora, tanto em 
ratinhos como em humanos44,65,66 e controla a expressão de CD25 nas células T reguladoras, 
mas não nas células T activadas67. A adição de outros marcadores, nomeadamente FoxP3, 
para caracterização imunofenotípica enriqueceria muito a nossa avaliação. 
 
O defeito da timopoiese em doentes com ICV, anteriormente mencionado, pode contribuir 
para as baixas percentagens de CD4+CD25high nestes doentes, já que o timo é uma fonte 
primária desta subpopulação68. Por outro lado, a IL2 é importante tanto para indução de 
apoptose de células T auto-reactivas15 como na expansão e manutenção da função 
imunossupressora das células CD4CD25 à periferia38,69,70,71. A deficiência de IL2 em 
sobrenadantes de culturas após estimulação com mitogénios já foi descrita na ICV72,73 e tem 
sido atribuída à linfopenia74, a qual paradoxalmente se associa com a expansão de 
CD4+CD25high em diferentes contextos75. Na nossa população não encontrámos linfopenia ou 
diferenças significativas nas percentagens ou valores absolutos de linfócitos entre doentes 
com e sem DAI. Adicionalmente, não encontrámos correlação entre os valores absolutos de 
linfócitos e frequências de CD4+CD25high, tanto considerando o conjunto de todos os doentes, 
como avaliando os grupos de doentes com DAI e sem DAI separadamente. A avaliação da 
capacidade de produção de IL2 pelas células T seria interessante neste contexto. 
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Alguns autores têm sugerido a existência de variações quantitativas / funcionais das 
CD4+CD25high em função da idade60. Gregg et al relataram um aumento progressivo da 
proporção de células CD4+CD25high 76, interpretado como predominantemente derivado de 
expansão periférica, enquanto Tsaknaridis et al encontraram um declínio progressivo da 
actividade supressora das células CD4+CD25 77, sugerindo eventual relação com o declínio da 
função tímica. Na nossa população, como em outras séries55,56, não foi encontrada correlação 
entre a idade e a frequência de CD4+CD25high, quando considerada toda a população de 
doentes com ICV e controlos. Esta análise foi metodologicamente muito relevante, em virtude 
de terem sido encontradas diferenças significativas entre as idades dos grupos de doentes com 
e sem DAI. Por outro lado, o facto de não existirem diferenças significativas nas distribuições 
por idade entre controlos e doentes, não sugere ser a idade o factor responsável pelas 
diferenças significativas na frequência de CD4+CD25high entre estas duas populações. 
Curiosamente, foi encontrada uma correlação positiva significativa entre a idade e a 
percentagem de CD4+CD25high no subgrupo de doentes com DAI. O estudo da actividade 
supressora seria extremamente interessante, no contexto da hipótese de Tsaknaridis77. 
Foi também encontrada diferença significativa na frequência de CD4+CD25high quando 
comparados doentes com e sem diarreia crónica não infecciosa, sem diferença significativa na 
distribuição por idade entre estes 2 grupos. No contexto da doença inflamatória intestinal, 
outros autores descreveram diminuição das células CD4+CD5high no sangue periférico78, em 
simultâneo com aumento significativo das mesmas células na lâmina própria intestinal79. 
 No nosso estudo, não foram encontradas diferenças significativas na frequência de 
CD4+CD5high no sangue periférico, após estratificação dos doentes de acordo com presença / 
ausência de bronquiectasias, esplenomegália, proliferação linfoide ou granulomas.  
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Alguns estudos têm tentado estabelecer uma classificação da ICV que permita prever quais os 
doentes com potencial evolução para DAI, embora sem sucesso10. Propomos a deficiência 
quantitativa de células T CD4+CD25high como um marcador útil à identificação de doentes 
com maior risco de desenvolver DAI. Atendendo à elevada sobreposição encontrada nas 
frequências de CD4+CD25high entre doentes com e sem DAI e entre doentes e controlos, 
propomos que a quantificação seriada / prospectiva desta população seria provavelmente mais 
informativa do que determinações isoladas.  
Em doentes seleccionados, o re-estabelecimento / indução de tolerância dominante poderia ser 
tentado in vivo através da estimulação da expansão de células T reguladoras e/ou 
fortalecimento da sua actividade supressora ou da sua indução in vivo ou in vitro37,80,81. 
Ensaios envolvendo números limitados de doentes e usando IL2 sintética82,83,84 ou natural85 
demonstraram o seu potencial clínico, embora estudos envolvendo maior número de doentes, 
com seguimento mais prolongado e com objectivos clínicos bem definidos sejam necessários 
antes de ser considerada a sua aplicação na prática clínica.  
 
Confirmámos, numa população de 47 doentes com ICV, a elevada prevalência de DAIs nesta 
entidade (40,4%), sendo a autoimunidade a forma de apresentação em 8/47 (17%) dos doentes 
estudados. Sugerimos o doseamento de imunoglobulinas aquando do diagnóstico de DAI, um 
procedimento acessível, económico e que pode influenciar opções terapêuticas decisivas 
nestes doentes em particular, nomeadamente o início de fármacos imunossupressores e 
esplenectomia.  
Verificámos uma diminuição da frequência de células T CD4+CD25high na população de 
doentes com ICV quando comparada com controlos, particularmente acentuada no subgrupo 
de doentes com DAI. Estudos prospectivos, envolvendo séries com maior número de doentes, 
e idealmente uma avaliação fenotípica e funcional mais detalhada das células T 
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CD4+CD25high permitirão integrar de forma mais adequada os nossos resultados na 
patogénese da autoimunidade na ICV.   
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ABSTRACT 
 
Background: Several mechanisms have been proposed to explain the high incidence of 
autoimmune diseases (AID) in Common Variable Immunodeficiency (CVID). We aimed to 
evaluate AID frequency within a CVID population and to characterize patients with AID. We 
also investigated whether a quantitative defect in the immunoregulatory population 
CD4+CD25high could be associated with increased prevalence of autoimmunity in CVID.  
Methods: 47 patients with CVID on regular intravenous immunoglobulin substitution therapy 
were enrolled. Chart review and questionnaire-guided interview were used to collect clinical 
and laboratory data concerning presentation symptoms and clinical evolution, including AID. 
Serum immunoglobulins were quantified at diagnosis. A cross-sectional evaluation was 
performed before IVIG infusion, including serum IgG level, T, B and NK cell quantification 
by flow-cytometry in freshly whole blood. CD4+CD25+ cells were simultaneously quantified 
in whole blood by flow-cytometry and compared with age-matched healthy volunteers.  
Results: AIDs were diagnosed in 19 patients (40.4%) and autoimmune cytopenias were the 
most frequent. AID was diagnosed before CVID in eight patients, none on 
immunosuppressors in the year before CVID diagnosis. Patients with AID were older at the 
time of the present evaluation, at CVID diagnosis and at beginning of IVIG. They also 
exhibited higher prevalence of chronic non-infectious diarrhea and lymphoid hyperplasia and 
higher serum IgG at diagnosis. There were no significant differences in IgG pre-infusional 
levels and lymphocyte subpopulations between patients with and without AID. CD4+CD25high 
frequencies were significantly lower in patients with AID compared to those without AID and 
controls and in the whole group of CVID compared to controls.  
Conclusions: Our results suggest that CD4+CD25high deficiency may possibly contribute to 
the high incidence of AID in CVID. More detailed and longitudinal evaluation of 
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CD4+CD25high T cells in larger cohorts, including the use of additional markers and 
suppressor cells function assessment, will help to clarify this issue. 
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INTRODUCTION 
 
Common variable immunodeficiency (CVID) was described for the first time in 1953 by 
Janeway 1. It is nowadays the most frequently diagnosed primary immunodeficiency (PID) 
and the most common symptomatic congenital deficiency of the immune system. Its 
prevalence has been estimated as 1/25 000 in the western population 2,3 and worldwide it has 
been reported between 1/20 000 and 1/200 000 4,5. 
Diagnosis of CVID is established when there is marked decrease of two major serum 
immunoglobulin isotypes, usually IgG and IgM and/or IgA, over two standard deviations 
(SD) below mean values for age 6, in addition to impaired ability to specific antibody 
production after vaccination or exposure to a known infectious agent. Other primary or 
secondary causes for antibody deficiency should be excluded 7,8. 
The most common clinical manifestations of CVID are recurrent pyogenic infections, usually 
by encapsulated bacteria and involving the sino-pulmonary tract, or otherwise unexplained 
chronic lung disease. Gastrointestinal manifestations are also frequent, either infectious, 
involving bacterial and protozoal agents or inflammatory conditions, leading to chronic 
diarrhea and malabsorption. In addition, CVID is associated with a remarkable incidence of 
autoimmunity and increased risk of gastric cancer and lymphoma 9 and other clinical 
presentations of benign lymphoid proliferation, including multiple adenopathies, 
splenomegaly and lymphocitic or granulomatous infiltration of lungs, lymph nodes or other 
sites 8,10,11. In some cases, non-infectious complications dominate the clinical picture of CVID 
and have a significant impact on the overall severity of the disease.  
Although included in the last update of the International Union of Immunological Societies 
(IUIS) classification of PIDs as predominantly an antibody deficiency 6, many other 
immunological defects have been reported in patients with CVID, involving both innate and 
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acquired immunity, including both humoral and cellular components, and mostly the interplay 
between all 3,12,13. The possibility of extensive immunological heterogeneity underlying the 
wide diversity of presentation symptoms and clinical outcome has motivated recent works 
aiming to individualize groups of patients based on clinical features and match them to 
particular immunological defects. On the other hand, interest on a possible genetic basis of 
CVID has increased and, in the last 2 years, four monogenic defects associated with CVID 
have been identified: ICOS, TACI, BAFF-R and CD19 2, 12. 
Autoimmune disease (AID) prevalence has been estimated as 5-7% in the general population 
14. In one of the largest CVID series reported in the literature, Cunningham-Rundles et al refer 
to AID in 52/248 (21%) patients 15. More recently, other authors have reported higher 
incidences ranging from 28% 4 to 50% 5,16,17. Several mechanisms have been proposed to 
explain this high incidence of autoimmunity in CVID, although no immunological marker of 
autoimmunity has been identified in these patients.  
Among different T cell sub-populations known to participate in the maintenance of tolerance, 
CD4+CD25high lymphocytes have emerged as a major immunoregulatory population. Besides, 
evidence is now accumulating that regulatory T cells are also involved in the down-regulation 
of allergy, graft-versus-host disease and immune response to tumors and infections 18,19.  
Although results are not consensual 20,21,22, quantitative 23,24,25 or functional 26,27,28,29 defects in 
CD4+CD25high cells were found in some human AID. Even though a possible functional 
compromise of suppressor T cells promoting the growth of autoimmune clones in CVID has 
been suggested 30, the hypothesis of a quantitative defect in CD4+CD25high had not been 
investigated in this context.  
In the present work we aimed to evaluate AID frequency within a CVID population and to 
characterize a group of patients with CVID and AID, both from clinical and immunological 
point of view. We also investigated whether a quantitative defect in CD4+CD25high in CVID 
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patients could be associated with an increased prevalence of autoimmunity. This could be 
either a defect of a particular homogenous group with clinical expression of AID or a 
common defect to the general population of CVID.  
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PATIENTS AND METHODS 
 
A retrospective and descriptive study of AID prevalence was performed among a CVID 
population followed at Vall d´Hebron Hospital, a referral center for both pediatric and adult 
primary immunodeficiency patients in Barcelona, Spain. Clinical history from all patients was 
carefully reviewed concerning presentation symptoms and complications. A cross-sectional 
laboratory evaluation of these patients was also performed in the Immunology Department at 
the same institution. Institutional review board approval was obtained for this study. 
 
Patients 
The study included 47 patients (22 women / 25 men; mean age: 37.5 ± 15.9; range: 16-71 
years old) attending Vall d´Hebron between January and March 2004 and with a mean follow 
up of 8.8 ± 6.1 years since CVID diagnosis. All patients were on regular intravenous 
immunoglobulin (IVIG) substitution therapy. Diagnostic criteria were according to WHO 6 
and ESID recommendations 7. Each patient presented a marked decrease in at least two out of 
the three major isotypes of serum immunoglobulins (IgG, IgA and IgM) by more than two SD 
below mean values for age on at least two separate occasions over one month. In most cases, 
including all patients with serum IgG level greater than 350 mg/dL, antibody deficiency was 
verified by means of decreased isohemaglutinins and / or antibody production to two or more 
vaccines, including tetanus, Haemophilus influenzae and pneumococcal vaccine. These 
patients were immunized with Haemophilus influenzae type B (Hib)-conjugated vaccine 
PedvaxHIB® and PNU-Immune23® polyvalent pneumococcal vaccine and titers of specific 
IgG before and four weeks after immunization were compared 31,32. 
Subjects under the age of two years and all patients with known secondary causes of 
hypogammaglobulinemia at time of CVID diagnosis were excluded, namely hematological 
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disorders such as myeloma or non-Hodgkin lymphoma, HIV infection, nephrotic syndrome, 
exsudative gastroentheropathy, thymoma, chronic immunossupression or catabolic states due 
to malnutrition, treatment with drugs like hydantoin and gold salts. Patients with other known 
causes of primary hypogammaglobulinemia (hyper IgM syndrome, X-linked 
agammaglobulinemia, X-linked lymphoproliferative syndrome) or low peripheral B cell 
counts (<1% CD19+ cells) were also excluded. 
Written informed consent was obtained from all patients before enrollment. 
 
Clinical and laboratory data collection 
Clinical and laboratory data concerning family history, first symptoms suggesting PID, CVID 
diagnosis, immunoglobulin replacement and clinical evolution, including complications / 
concomitant disorders and respective treatment have been collected by a single investigator 
by means of retrospective chart review and questionnaire-guided personal interview with all 
patients. 
Vall d´Hebron’s CVID follow-up protocol includes regular laboratory tests (hemogram, 
hepatic and renal function, PCR for HCV and HIV antigenemia, pre-infusion IgG level, stool 
and sputum cultures), imaging evaluation (annual abdominal ultrasonography and chest X-
ray, biannual abdominal and thoracic CT) and annual lung function. Further examinations are 
performed when appropriate, in selected patients, in order to diagnose / treat concomitant 
diseases, mainly infectious, autoimmune or malignant. AIDs have been diagnosed by the 
assistant physicians or by the investigator, according to accepted criteria for each disease and 
based on typical clinical data and laboratory / imagiological exams and exclusion of other 
frequent diagnosis. The absence of autoimmune antibodies did not exclude AID diagnosis.  
Serum IgG, IgA and IgM at diagnosis were quantified by nephelometry (reference values in 
individuals older than 16 years old were considered 850-1600mg/dL for IgG, 75-350mg/dL 
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for IgA and 58-250mg/dL for IgM). IgG subclasses were quantified by ELISA (reference 
values in adults were 261-1081mg/dL for IgG1, 112-408mg/dL for IgG2, 22-288mg/dL for 
IgG3 and 5-156 mg/dL for IgG4) 33. Adequate responses to the 23-valent pneumococcal 
vaccine 32 and the Hib conjugated vaccine 31 were considered when, respectively, four-fold 
and two-fold increases in specific IgG titer were verified by ELISA.  
 
Cross-sectional laboratory evaluation - CD4CD25high quantification 
A 10mL sample of peripheral blood in 0.05% EDTA was collected from CVID patients, prior 
to IVIG substitution. IgG level was quantified by nephelometry in this sample. Full blood 
counts, including white blood cell differential count were performed using a routine 
hematology analyzer in the Department of Pathology of Vall d´Hebron Hospital.  
Peripheral blood mononuclear cells (PBMC) were isolated by Fycoll-Hypaque gradient. CD4+ 
and CD8+ T cells, B cells and NK cells were assessed in the Immunology Department by flow 
cytometry (FACSCalibur, Becton Dickinson Biosciences, San Jose, CA, USA) using the 
following monoclonal antibodies (Becton-Dickinson®): anti-CD3, anti-CD4, anti-CD8, anti-
CD19 and anti-CD16 + anti-CD56. Anti-HLA-DR was used to assess CD4 and CD8 T cells 
activation.  
CD4+CD25+ cells were quantified in whole blood in parallel experiment using 3 colour 
acquisition on a Fluorescense Activated Cell Sorter FACSCalibur (Becton-Dickinson®), with 
peridinin chlorophyll protein (PerCP)-conjugated anti-CD4 (Becton Dickinson®), fluorescein 
isothiocyanate (FITC)-conjugated anti-CD25 (Immunotech®), phycoerythrin (PE)-conjugated 
anti-CD45RO (Becton Dickinson®) and respective mouse isotype controls.  
A single investigator with no access to clinical data acquired and analyzed all data using 
Cellquest software (Becton-Dickinson®). 
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Lymphocytes were gated according to forward and side scatter and a minimum of 10 000 
events were acquired and analyzed. CD4+CD25high definition adopted in this work was based 
on Baecher-Allan et al 34, in which CD4+CD25high cells appear as a tail to the right from the 
major population containing both CD4+CD25low and CD4+CD25- cells (Figure 1). 
CD4+CD25high percentage was defined as the percentage of CD25high within gated CD4 
positive T cells and its absolute number was calculated by multiplying this percentage by the 
number of CD4 positive T cells obtained in simultaneous sample. CD4+CD25high percentages 
obtained in patients were compared with those obtained in 29 age-matched healthy volunteers.  
 
Statistical Analysis 
Descriptive values of variables were expressed as the mean ± SD. CD4+CD25high percentages 
were compared using unpaired Student´s T test or Mann-Witney U test. Pearson´s correlation 
coefficient, Spearman´s rank correlation and Fisher exact test were used when appropriate to 
study the relationship between clinical and / or laboratory parameters. Statistical analyses 
were performed using Excel and Prism Graph Pad 4 Programs (GraphPad Prism, USA). 
Results were considered significant at a p value <0.05. 
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RESULTS 
 
3.1 Autoimmune diseases in patients with CVID 
Chart review and personal interview with the 47 patients revealed that 19 patients (40.4%) 
presented previous or present manifestations of AID (9 men and 10 women; mean age 46.5 ± 
15.0 years old). 
Twenty-six AID were diagnosed, including Evans´s Syndrome (1), immune 
thrombocytopenia (ITP) (5), autoimmune hemolytic anemia (1), pernicious anemia (4), 
eritroblastopenia (1), rheumatoid arthritis (3), vitiligo (1), alopecia areata (3), psoriasis (2), 
Sjogren’s Syndrome (1), autoimmune hepatitis (1), Crohn’s Disease (2) and primary 
hypothyroidism (1).  
Table 1 details AID diagnosis, age at presentation and AID treatment of the 19 patients. Six 
patients had more than one AID, with autoimmune cytopenias being the most frequently 
diagnosed (26.3%). In eight patients (patients 12 to 19), AID was diagnosed before CVID 
diagnosis (mean delay 13.6 ± 10.3 years; maximum delay 29 years). After starting symptoms 
of AID, patients 13, 14, 15, 16, 17, 18 and 19 were treated with oral steroids during variable 
periods but not in the year before CVID diagnosis were made. Investigations that lead to 
CVID were mainly prompted either by frequent respiratory infections (patients 12, 13, 14, 15 
and 19) or recurrent bouts of autoimmune cytopenias (patients 16 and 18). Patient 17 was 
diagnosed CVID when she was 14 years old. She presented with vitiligo and autoimmune 
hepatitis when she was nine years old. IgA deficiency was then diagnosed and small doses of 
oral steroids and azathioprine were prescribed during one year.  
At the time of the present study laboratory evaluation (including CD4+CD25high), patients 6 
and 13 were the only ones on immunosuppressive therapy - cyclosporine for Crohn’s disease,  
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3.2 Other clinical features of patients with AID  
First symptoms of CVID were recurrent respiratory infections in 11 cases and AID in the 
other eight, with mean age at the beginning of symptoms of 20.9 ± 15.6 and 21.2 ± 13.8 
years old respectively, as described in Table 2. Mean age at CVID diagnosis was 46.5 ± 15.0 
years old (minimum 10; maximum 58). There were no significant differences in age at the 
beginning of symptoms or at diagnosis between patients whose first symptoms were of AID 
and those who initially presented with upper or lower respiratory infections and developed 
AID during evolution (n=11).  
Sixteen patients presented recurrent upper and lower respiratory infections and bronchiectasis 
during evolution in association with chronic productive cough in eight and sinusitis in 11 
patients.  
Twelve patients reported intermittent periods of diarrhea with no infectious cause identified in 
stool cultures and intestinal biopsies. In four of these patients lymphoid nodular hyperplasia 
was found in intestinal biopsy, possibly justifying chronic diarrhea. Eight patients had 
recurrent infectious diarrhea and Giardia lamblia was the most frequent cause. Only six 
patients did not present gastrointestinal symptoms. 
Lymphoid hyperplasia, defined as the presence of splenomegaly and / or lymphadenopaties, 
was found in 12 patients. Patients 1 and 13 were splenectomized for uncontrolled autoimmune 
cytopenias at 39 and 13 years old, respectively, and presented lymphadenopaties in both 
cases. Three patients had granulomatous disease, which may have been underdiagnosed, as 
biopsies were not performed in all patients. There were no reports of malignancy during 
clinical evolution.  
All patients were on IVIG replacement therapy, with highly variable doses and periodicity, 
individually adapted to each patient’s weight and clinical condition (668 ± 402 mg/Kg/month; 
373-1820 mg/Kg/month).  
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3.3 Immunological features of patients with AID  
Levels of immunoglobulins and IgG subclasses at time of diagnosis of CVID in patients with 
AID are detailed in Table 3, which also shows hemogram, lymphocyte subsets evaluation and 
pre-infusional IgG cross-sectional results. 
Three patients were diagnosed CVID before 18 years of age (patients 6, 15 and 17) and the 
remaining 16 after the third decade of life. Considering the normal range of serum 
immunoglobulins for each age, IgA and IgG were decreased in all patients, although IgG at 
diagnosis was above 350mg/dL in 12 of them. IgM was not decreased in five patients.  
Hemogram within cross sectional study revealed anemia (hemoglobin <11g/dL) in patients 10 
(pernicious anemia) and 13 (ferropenic anemia) and thrombocytopenia (platelets 
<100000/mm3) in patient 3 with a previous diagnosis of ITP. Lymphopenia (lymphocytes 
<1000/mm3) was detected in four patients and CD4 lymphopenia (<500/mm3) in eight. An 
inversion of CD4/CD8 (<1) was found in five patients. All patients had more than 2% B 
lymphocytes, although four of them presented less than 100 cells/mm3. 
Serum IgG level obtained before immunoglobulin infusion was highly variable (mean 695.9 ± 
181.5 mg/dL) and was under 500 mg/dL in two patients.  
 
3.4 Comparison between patients with and without AIDs  
Clinical and immunological features of patients with and without AID are compared in Table 
4. Patients with AID were significantly older than patients without AID when this study was 
performed (p=0.0017, Figure 2) and at first symptoms of CVID, although this difference was 
not significant. Mean delay between first symptoms and CVID diagnosis was significantly 
longer in patients with AID (p=0.022) and patients with AID were significantly older both at 
CVID diagnosis (p=0.0022) as well as at the beginning of IVIG therapy (p=0.004).  
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When comparing patients with first symptoms of AID (n=8) with those with other types of 
clinical presentation (n=39) there were no significant differences in age at beginning of 
symptoms or at CVID diagnosis. Nevertheless, among patients that did not present initially 
with AID (n=39), mean delay until diagnosis was significantly longer in those that developed 
AID during clinical evolution (p =0.029). 
Patients with AID presented significantly higher prevalence of chronic non-infectious 
diarrhea (p=0.015) and lymphoid hyperplasia (p=0.043) than patients without AID, but 
frequency of splenomegaly was not significantly different between these two groups.  
Regarding laboratory evaluation, IgG serum level at diagnosis was remarkably lower in 
patients with no AID (p=0.0009). Grouping the 47 patients according to type of clinical 
presentation, IgG level at diagnosis was also significantly higher in the 8 patients who 
initially presented with AID than in those with other types of first symptoms (respectively 413 
± 87 mg/dL and 270 ± 146 mg/dL; p=0.002). There were no significant differences in recent 
pre-infusional IgG levels or hemogram counts between patients with and without AID.. 
Leukocyte differential count, lymphocyte subpopulations and HLA-DR expression both in 
CD4+ and CD8+ T cells were comparable in both groups, with no significant differences in 
absolute values or percentages. 
 
3.5 CD4+CD25high
CD4+CD25+ T cells and CD4+CD25high T cells were analyzed as illustrated in Figure 1 and 
results are shown in Table 5. CD4+CD25+ T cells frequency was significantly lower in 
patients with AID, both when compared with those without AID (p=0.0199) and with controls 
(p=0.041), as shown in Figure 3(A). When considering percentage of CD4+CD25high within 
CD4+ T cells, these differences were more significant, being these percentages lower in 
patients with AID both comparing with patients without AID (p=0.0016) and with controls 
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(p<0.0001). A significant difference was also found when evaluating the whole group of 
CVID and controls (p=0.011), with mean CD4+CD25high lower in the first group, as shown in 
Figure 3(B). These differences in CD4+CD25high frequency maintained statistical significance 
(p=0.0038, p<0.0001 and p=0.023, respectively) after exclusion of the two patients under 
treatment with cyclosporine.  
A significant difference was found in current age between patients with and without AID 
(Figure 2). No correlation was found between age and CD4+CD25high frequency in the control 
group or in the whole group of patients, but interestingly there was a significant positive 
correlation in the subset of patients with AID (Spearman r=0.47; p=0.04; Figure 4). No 
correlation was observed between the degree of lymphopenia and levels of CD4+CD25high, in 
spite of lymphopenia having been described to be associated, in different contexts, with 
CD4+CD25high increase 35.  
Simultaneous staining of CD4, CD25 and CD45RO showed that the large majority of 
CD4+CD25high in the cohorts were in fact CD45RO+ (more than 96%). T regulatory (T reg) 
cells have been described as mostly CD45RO+ 34a, as it was seen in this population, both in 
CVID patients with and without AID and in controls. There was no correlation between 
CD4+CD25highRO+ and lymphopenia, CD4+ or CD8+ absolute values or percentages within 
lymphocytes. CD4+CD25highRO+ were also not correlated with absolute numbers or 
percentages of HLA-DR+ cells within CD4+ or CD8+ T lymphocytes.  
Correlation of CD4+CD25high percentages with other clinical data was also studied. The only 
significant difference in levels of CD4+CD25high was found when comparing patients with and 
without chronic non-infectious diarrhea (CD4+CD25high respectively 0.697 ± 0.371% and 
1.119 ± 0.711%; p=0.011), with no significant difference in ages between these two groups.  
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DISCUSSION 
The high incidence of autoimmunity in primary immunodeficiencies represents an apparent 
paradox of immunology that has congregated growing interest among immunologists in the 
last years 36,37,38. Several authors have suggested that autoimmunity and immunodeficiency 
are not mere contraries but different facets of a dysregulated immune system 39,40. PIDs were 
once considered as limited to those clinical conditions with increased incidence or severity of 
infectious diseases, but nowadays it is clear that PIDs are also characterized by increased 
susceptibility to cancers (especially lymphomas), autoimmune diseases and in some cases, 
dysregulated inflammation due to abnormal infiltration of lymphocytes in tissues and organs 
41. AIDs are common manifestations not only in CVID but also in other PIDs, namely IgA 
and C2 deficiencies 41.  
The high incidence of both cellular and autoantibody-mediated AIDs in CVID that is mainly 
characterized by a deficit of antibodies production suggests that more complex defects in 
immune system, beyond quantitative and qualitative defects in antibodies production 5, should 
underlie its high diversity in clinical manifestations. An increasing list of immune defects has 
been reported in the last years, including B and T cell defects besides B-T cooperation and 
innate immunity impairment. In most cases, these defects are not universal to the whole CVID 
population, but affect subgroups with varying degrees of severity. CVID is though presumed 
to congregate a heterogeneous group of disorders with separate etiologies and distinct clinical 
and immunologic features 6,42.  
Several authors have tried to develop a classification of CVID patients based on 
immunological profile with clinical correlates. This would allow physicians to create follow-
up protocols adjusted to each group of patients, optimizing the screening and diagnosis of 
complications and respective treatment. The identification of homogeneous groups of 
patients, from clinical and immunological point of view, would further allow pursuing genetic 
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investigation and, eventually, the identification of different entities amongst CVID. Patients 
with AIDs may constitute one of those homogenous groups and their extensive clinical and 
laboratory characterization may contribute to a better understanding of the etiopathogenesis of 
this situation.  
We present a group of 47 patients with CVID followed at Vall d´Hebron Hospital. In our 
series, 19 patients (40.4%) presented with AID either before or after CVID diagnosis. 
Cunninghan Rundles et al reported AID in 52/248 (21%) patients from multiple institutions, 
excluding 7 with anti-IgA antibodies and no symptoms 15. Nevertheless, higher incidences 
have been recently reported, ranging from 9/32 (28%) 4 to 20/40 patients (50%) 16. This wide 
variability may be influenced by differences between CVID populations studied, but also by 
heterogeneity in AID diagnostic criteria used in each study. There are increased difficulties in 
the diagnosis of autoimmunity in CVID, since autoantibodies, that are usually decisive criteria 
in supporting AIDs diagnosis, may be absent as part of antibody secretion impairment 5,43. 
Conversely, as in the general population, autoantibodies may be detected in absence of 
clinical AID in CVID patients 17. Moreover, serological methods are of no value in patients 
under IVIG replacement therapy and therefore should not support AID in this context.  
Autoimmune cytopenias were the most frequently diagnosed AIDs in our population, in 
agreement with reports from several authors16,44. In our series, autoimmune cytopenias were 
diagnosed in 6/47 patients (12.8%) of the whole population. This frequency is very similar to 
the prevalence of hematological autoimmune manifestations found in a series of 326 patients 
with CVID (11%), in which ITP has been the most frequent cytopenia 10. A multi-center 
retrospective study in France involving 105 CVID patients described an even higher 
prevalence of ITP (20%)43. Incidences of both ITP and AIHA are strikingly lower in the 
general population, respectively 1.0-12.5 per 100 000/year 45 and 1-3 per 100 000/year 46.  
 
 
 
48 
Autoimunidade e células reguladoras T CD4+CD25High na Imunodeficiência Comum Variável 
 
Rheumatoid arthritis (RA) and pernicious anemia were the second most frequent diagnosis of 
AID in our population (6.4% each). Aseptic polyarticular arthritis that resembles RA, 
although frequently non-erosive, has been observed in 10-30% of CVID patients 30, 47. 
Autoimmune arthritis is characterized by symmetric involvement of joints, most often the 
knees, ankles and hands; it is rarely destructive and rheumatoid factor and antinuclear 
antibodies are typically absent. Diagnosis of RA is difficult in CVID patients, as serological 
diagnosis of RA is not reliable and other causes of arthropathy should be excluded, namely 
infectious and amyloidosis. Presence of HLA DRB1*01 antigens was proposed as helpful in 
early RA diagnosis 48.  
Many other AIDs have been described in patients with CVID, both involving AIDs that have 
been formerly associated with predominant humoral and cellular immunity. Some of the AIDs 
we found in our population had been previously reported in CVID patients, namely pernicious 
anemia 49, vitiligo 49,50, psoriasis16 and inflammatory bowel disease30. In the literature, there 
are reports of many other AIDs in CVID patients, including juvenile rheumatoid arthritis 51, 
primary biliary cirrhosis 4,49, alopecia totalis 4,52, Systemic Lupus Erythematosus (SLE)-like 
syndromes 53,54, vasculitis 15, Insulin Dependent Diabetes Mellitus 5,52,55, celiac disease 56, 
Guillain-Barré Syndrome 47, myasthenia gravis 4 and autoimmune thyroiditis 52.  
Considering the 47 patients we evaluated, there was a slight non-significant predominance of 
males (53.2%), which is not in agreement with any known preferential incidence of CVID in 
the male gender 5. Other authors have reported that autoimmune phenomena in CVID patients 
are more frequent among female, which has been stressed by a study, in which 61% of the 
patients with AID were female15. In fact, when considering the whole population in that study, 
prevalence of autoimmunity was not significantly different between the 102 men (25.4%) and 
146 women (27.4%). Similarly, in our series, AIDs prevalence among females (10/22 – 
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45.5%) was higher than among men (9/25 - 36%), although this difference was not 
significant.  
In our population, age at beginning of symptoms attributed to CVID was quite variable; mean 
age at presentation was 15.6 ± 14.7 years old (minimum 4; maximum 51). First symptoms 
occurred earlier in our population when compared with other studies 5,15. Cunningham-
Rundles et al reported 248 patients with mean ages at symptoms beginning of 23 and 28, 
respectively in males and females 15. Nevertheless, comparisons are complex concerning this 
parameter, as its evaluation is difficult based on retrospective studies that are frequently 
dependent on patients’ awareness and memory and on the investigator’s valorization of initial 
manifestations, which may be influenced by a previous diagnosis of CVID. Hermaszewski et 
al 29 and more recently Salzer et al 2 have reported a bimodal age at beginning symptoms, 
including two peaks, being the first one in the first decade of life and the second in early 
adulthood, although, less frequently, later presentations have also been described 16. 
In our series, we found mean age at diagnosis of 28.4 ± 17.6 years and mean delay since first 
symptoms to diagnosis 12.8 ± 12.4 years, which is similar to what has been reported by other 
authors 4,5,15,43. Patients with AID were not significantly older at the beginning of symptoms, 
but mean delay until CVID diagnosis was significantly longer in these cases (p=0.022). 
Interestingly, no significant differences were found in age at presentation or delay to 
diagnosis when comparing patients with AID as initial presentation (n=8) with those with 
other initial presentations (n=39), although a significant longer delay to CVID diagnosis was 
found in patients with AID during evolution but with a different initial presentation (n=11) 
than patients with no AID (p=0.029). In some cases, AID might have been missed as a 
possible PID manifestation thus contributing to a longer delay to CVID diagnosis.  
AIDs are frequently the first manifestation of CVID or other primary antibody deficiencies, 
sometimes with no previous remarkable history of recurrent / severe infections 17,43 as it 
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happened in eight of our 19 patients with AID. Cunningham-Rundles et al reported that 
autoimmune hematological diseases appeared prior to CVID diagnosis in 54% of the cases 
described in a series of 326 patients 10. In another study 43, ITP was first diagnosed in 62% of 
21 patients with ITP and CVID and these two diseases were diagnosed simultaneously in four 
patients. Notably, a serum protein electrophoresis was performed in only one of the patients 
who were first diagnosed ITP and showed no abnormalities 43. 
The use of immunosuppressive therapy in patients with first diagnosis of AID may disturb 
PID diagnosis. The etiopathogenesis of CVID in this context may be questioned as drugs used 
in AID treatment, namely sulfasalazine, gold salts, D-penicilamine, oral steroids and other 
immunossupressors may cause hypogammaglobulinemia 48. More severe 
hypogammaglobulinemia 4 and longer period between immunosuppressive therapy and CVID 
diagnosis are usually mentioned to support the primary character of hypogammaglobulinemia. 
Both hypotheses must be considered in a critical evaluation of these patients 53,57,58,54,59,60,61. 
Among our eight patients that initially presented with AID, none was on immunosuppressive 
therapy when CVID was diagnosed.  
Immunoglobulin quantification when an AID is diagnosed has been a subject of controversy. 
The American Society of Hematology considered routine screening of serum 
immunoglobulins unnecessary and inappropriate in children but did not comment on adults in 
its practice guidelines for ITP 45. Conversely, Heeney et al suggested quantitative 
measurement of serum immunoglobulins in children with autoimmune cytopenias, especially 
in those with a chronic or recurrent course 62. Some authors have recommended 
immunoglobulin quantification when an AID is diagnosed, irrespective of patient’s age, even 
in the absence of previous recurrent / severe infections suggesting PID, in particular when 
patients are going to start immunosuppressive therapy 17,43,55. Given the increased incidence of 
AID in PID, we would support this proposal, as serum protein electrophoresis and 
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nephelometry are fairly inexpensive and accessible laboratory methods. Diagnosis of PID 
would have a major impact on these patients follow-up, particularly regarding therapeutic 
options that may include immunosuppressive drugs and splenectomy, and early / aggressive 
treatment of infections.  
Possible benefits of an early IVIG substitution, with the aim of control and prevention of 
AIDs, namely autoimmune cytopenias, have been debated. It has been suggested that the 
decision to treat a patient with IVIG replacement should be based not only on the frequency 
and severity of infections, but also on the severity of autoimmune manifestations 63. In 
particular, in X-linked agammaglobulinemia patients with AIDs, Etzioni A. reported that 
increased dose of IVIG could ameliorate their condition 39.  
Based on the fact that ITP has been diagnosed in patients with CVID after starting IVIG 
treatment, Michel et al suggested that IVIG was notoriously ineffective in CVID-associated 
ITP when given at only 0.5 g/kg and did not influence its natural history when administered 
repeatedly, even at higher doses (1-2 g/kg, every 3 weeks) 43. In opposition, Cunningham-
Rundles et al reported that 30/35 (86%) patients with CVID developed hematologic AID 
either before or concurrent with CVID diagnosis and institution of IVIG (p<0.0001) and thus 
suggested that IVIG replacement therapy diminishes the occurrence of those conditions 10. 
Moreover, Bloch Michel et al suggest benefits of substitutive treatment with IgG in the 
control of thrombocytopenia after corticotherapy 5.  
In the literature, there are no controlled randomized studies showing the benefits of an early 
IVIG start relating to autoimmunity control and IVIG immunomodulatory activity has been 
claimed to immunomodulatory doses that are far above replacement doses currently used in 
CVID patients. Therefore, many groups tend to delay IVIG start while patients are free of 
severe or recurrent infections 62.  
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In our series, cytopenias and other AID evolution were benign most cases. The majority did 
not require systemic immunosuppressive therapy, except for occasional oral steroids, 
similarly to what has been reported by Warnatz et al 16. Only patients 6 and 13, both with 
refractory Crohn’s disease, were on current immunosuppressive therapy (cyclosporine) when 
evaluated. In other series, patients with cytopenia and unsuspected CVID had a more severe 
clinical course, characterized by chronic and recurrent cytopenia16. 
Besides the older age at diagnosis, we found that patients with AID presented significantly 
higher prevalence of chronic non-infectious diarrhea and lymphoid proliferation than patients 
without AID, although splenomegaly incidence was not significantly different between these 
two groups. Regarding laboratory evaluation, no significant differences were found between 
the two groups, except for patients with AID presenting higher mean IgG at diagnosis than 
patients without AID. IgG at diagnosis was even higher in patients initially presenting with 
AID. The high values of serum IgG frequently found in autoimmunity may possibly have 
contributed to the delay in CVID diagnosis in these patients.  
 
Different hypotheses have been raised to explain the increased incidence of AIDs in CVID41:  
1 – Genetic predisposition to autoimmunity.  Although most cases of CVID are sporadic, 
about 10-25% of the patients report family history of humoral PID, including CVID, 
displaying either autossomal dominant or recessive modes of inheritance 2,4,64. There is 
obvious familiar clustering of IgA deficiency and CVID, suggesting that genetic factors play 
an important part in CVID genesis3. Genetic linkage and haplotype analysis have shown that 
IgA deficiency and CVID share a major susceptibility locus in the HLA-DQ-DR haplotype on 
chromosome 6 3,64,65, a region where alleles have been associated with SLE and celiac disease 
30. CVID has also been significantly linked to the haplotype HLA-A1-B8-DR3, which is 
associated with autoimmune disorders such as SLE 5.  
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2 - Infection as the link between immunodeficiency and autoimmunity 40. Defective processing 
and clearing of external antigens from mucosal surfaces and abnormal handling of 
superantigens66 may result in chronic inflammation and eventually in end-organ deposition of 
immune complexes, formation of anti-tissue antibodies or in cross reactivity between normal 
tissues and foreign antigens. Chronic EBV infection and increased exposure to organisms 
sharing epitopes with host constitution (molecular mimicry) may contribute to the activation 
of auto-reactive T cell clones 30.  
Many immunological defects have been reported in CVID patients that may help 
understanding their inability to clear external antigens including a possible genetic 
predisposition to abnormal antigen handling 67. 
A disturbed B cell function, with both early 68 and late B cell differentiation defects 69 
including defects in up-regulation of CD70 and CD86 in naïve B cells 70,71, in signaling 72, 
somatic hypermutation 73,74,75 and impaired antibody affinity maturation 75 has been 
demonstrated in different studies. Different authors have reported B maturation defects with 
reduced populations of CD27+ memory cells and lack of IgD-IgM-CD27+ class-switched 
memory B cells and plasma cells76 and increased percentages of undifferentiated B cells in 
peripheral blood of patients with CVID 77, 78, 79,80. 
Besides humoral deficiency, T cell function compromise affects a large proportion of CVID 
patients 13,15,81. T cell help is required for successful B cell maturation and impaired 
expression of T cell surface molecules may be responsible for the failure of B-cell 
differentiation and for the inability to generate a proper immune response, thus converting 
CVID more properly in a combined PID. In some patients, B cells secrete normal amounts of 
immunoglobulins when appropriately stimulated in vitro, suggesting that T cell dysfunction 
leading to inadequate B cell help, plays an important pathogenic role 82. Vlková et al have 
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recently focused on mutual relations in T and B lymphocyte abnormalities in CVID and 
proposed that these are partially related to each other 83.  
Decrease in absolute numbers of T cells has been described in approximately one third of 
CVID patients84, due to reduced CD4+ T cell subset, mostly naïve CD4+CD45RA+ 85,86 but 
also antigen-specific memory CD4+ 87,88. Inversion of CD4+/CD8+ ratio is frequent in CVID 
84,89. Many explanations have been proposed to T lymphopenia in CVID including deficient 
thymopoiesis 3 and IL2 production 90, abnormalities in IL7-mediated lymphocyte homeostasis 
91 and/or increased apoptosis due to persistent antigen activation following infections 92,93, 
increased oxidative stress in CD4+ cells 94 or spontaneous apoptosis, associated with increased 
CD95 expression in CD4+ and CD4+CD45RA+ subsets 93. 
De Vera et al reported a significantly increased level of T-cell receptor-rearrangement 
excision circles (TRECs) in a group of patients with CVID compared with age-matched 
controls, although with an accelerated decline of TREC levels with age, both in CD4+ and 
CD8+ T subsets 95. This may be in association both with a more rapid reduction of thymic 
output in CVID individuals with age and/or with enhanced cellular activation and 
proliferation in CD4 and CD8 peripheral compartment. Isgro et al reported a reduction of 
CD31+ recent thymic emigrants in a group of patients, in which decreased numbers of CD4+ T 
cells were present in a large proportion of patients96. Differences between these studies have 
been partially attributed to the heterogeneity of populations and different methods employed.  
Isgro et al have also shown a reduced content of primitive progenitors in bone marrow 
mononuclear cells of CVID patients, besides abnormal stromal cell composition and cytokine 
production with increased TNFα production and decreased IL2 production 96.  
T cells functional defects include decreased T cell activation and proliferation 15,97 dependent 
on impairment of early signaling events 98,99,100,101 or integration of activating signals derived 
from TCR and co-stimulatory molecules 102, both in CD4+ and CD8+ T cells. In a subgroup of 
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patients with impaired T cell proliferation, predominance of CCR7- effector-memory T cells 
was reported 103. CCR7- T cells are a subset of tissue-homing, memory T cell population with 
reduced proliferative capacity, IL2 secretion and CD40L expression. Reduced expression of 
cell surface molecules in some CVID patients, namely CD40L 104, attractin 105 or L-selectin 
106 has also been reported. 
Defects in innate immunity may additionally contribute to reduce external antigens clearance. 
Defective differentiation and maturation of dendritic cells, with decreased expression of co-
stimulatory molecules CD80, CD86 and HLA-DR and impaired IL12 production 107,108,109 
were described in some patients with CVID. Absolute and relative decreases in NK cell 
numbers 110 and impaired NK-mediated cytotoxicity 3 have also been reported. Phagocytosis 
by monocytes 111 may be compromised by defective opsonization mediated by Fc, 
complement receptors CR1 and CR3. Low producing coding alleles and promoter haplotypes 
for mannose binding lectin were correlated to an early age of disease onset and increased 
autoimmune disease incidence67.  
3 - Increased incidence of AID as part of immune dysregulation in CVID. Cytokine 
dysregulation has been reported with Th1 skewing 3, enhanced IFNγ production 3 and 
decreasing of production of Th2 cytokines, namely IL4, IL5 and IL10 112,113,114,115,116. 
Conversely, other authors have reported increased IFNγ production both in CD4+ and CD8+ 
lymphocytes 117.  
IL2 has been reported as important in triggering the apoptosis of auto-reactive T cells 40. A 
general reduction in IL2 secretion into culture supernatants following mitogenic stimulation 
of cultured CVID T cells is well known 112,118. This decrease may reflect the reduction in 
CD4+ T cells and particularly in CD45RA+ cells in CVID, as intracellular production of IL2 
by T cell following mitogenic stimulation is normal 117.  
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In addition, persistent activation of TNF system, described in a subgroup of patients 119, may 
contribute to autoimmune disorders and granuloma formation.  
Cell subpopulations equilibrium disturbances also contribute to immune dysregulation in 
CVID. Recent work has shown that patients with a more profound lack of isotype switched 
memory B cells are more likely to develop autoimmunity 16,79,120. Warnatz et al reported that 
patients with reduced numbers of switched memory B cells CD19+CD27+IgM-IgD- (<0.4% of 
total lymphocytes) had increased frequency of splenomegaly and autoimmunity79 and could 
be further subdivided in a group with more than 20% CD19highCD21lo/neg, comprising 
preferentially patients with splenomegaly and autoimmune cytopenias and a group with less 
pronounced expansion of these cells 16. Ko et al found higher rates of autoimmune and 
granulomatous disease in patients with increased proportion of immature B cells, which 
would possibly contribute to their enhanced autoantibody production 120,121. In contrast, 
Piqueras et al found no differences in prevalence of AID between CVID patients classified by 
switched / non-switched memory B cells frequency, but lack of these memory cells was 
associated with higher prevalence of splenomegaly, lymphoid proliferation and 
granulomatous disease 80. Bloch-Michel C et al 5 have divided CVID patients in 2 groups 
according to T lymphocyte activation degree, being group I with no AID or organomegalies 
and inactive T lymphocytes and group 2 with AID and/or organomegalies besides activation 
of T lymphocytes. The concurrent heightened susceptibility to AIDs and lymphoid 
proliferation in some series, including ours, has prompted the hypothesis that a common 
environmental antigen could trigger these manifestations 43 and remains an interesting topic 
for further investigation. 
4 - Breakdown in central and / or peripheral mechanisms of tolerance induction or 
maintenance. Failure in central tolerance mechanisms may lead to the persistence of 
autoantibodies by different mechanisms, including abnormal somatic hypermutation, failure 
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to delete self-reactive clones 73,122 or defective differentiation and maturation of dendritic cells 
which may compromise competent induction of immune tolerance through interactions with T 
and B cells3. Auto-reactive T cells are known to be present in the periphery in healthy 
individuals, as they escape thymic clonal deletion and induction of anergy. Regulatory T cells 
are involved in the maintenance of peripheral self-tolerance by actively suppressing the 
activation and expansion of auto-reactive T cells 123. The earliest experiences to suggest the 
existence of thymic generated specific regulatory T cells were by Nishizuka and Sakakura 124. 
Sakagushi et al denominated these cells as the CD4+CD25+ natural T reg and have shown that 
depletion of CD4+CD25+ suppressor cells results in the onset of systemic AID in mice 125. 
The same group later showed in animals that a minor population of CD4+CD25+ T cells was 
crucial for the control of autoimmune T cells in vivo 126,127. Many experimental organ-specific 
AIDs were induced in susceptible strains of mice by protocols that resulted in the complete 
removal or delay of the development of CD4+CD25+ T cells and the co-transfer of 
CD4+CD25+ T cells prevented the development of AID 19,127,128. Also CD25 deficient mice 
were demonstrated to be prone to severe autoimmunity that could be prevented by the 
inoculation of CD4+CD25+ T cells from syngenic mice 129. These accumulated data have 
strongly suggested that CD4+ T cells that naturally co-express the α-chain of the IL2 receptor 
(CD25) play an important role in the pathogenesis of AIDs.  
A population with identical phenotypic and functional properties in vitro was later defined in 
humans in peripheral blood, thymus and in umbilical venous blood from healthy newborn 
infants 34,130,131,132,133, preferentially residing within those CD4+CD25+ T cells with brightest 
expression of CD25 34. Despite the growing interest in CD4+CD25+ T cells role in the 
emergence of AIDs in animal models, very limited and controversial information is available 
on their role in the pathogenesis of human AIDs. Quantitative or functional defects in 
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CD4+CD25+ have been pointed as possibly involved in different AIDs, although some 
discrepancies were found between published reports. 
Different authors found a decrease in the number of circulating CD4+CD25+ in autoimmune 
diabetes 23, autoimmune hepatitis 24 and SLE 25,134 and functional impairment with normal 
numbers of circulating CD4+CD25+ T cells was detected in polyglandular syndrome type II 26, 
multiple sclerosis 27 and autoimmune diabetes 28,29. Other studies have failed to detect any 
deficiency in CD4+CD25high in myasthenia gravis 20, multiple sclerosis 21, autoimmune 
diabetes 22 and Sjögren’s syndrome 135. Interestingly, in rheumatoid arthritis, higher numbers 
of regulatory T cells with increased suppressive activity were found in synovial fluid from 
inflamed joints compared to peripheral blood 136,137, similarly to the reported increase of 
CD4+CD25+ T reg in intestinal mucosa of patients with inflammatory bowel disease 138. Sun 
et al suggested that in patients with myasthenia gravis, decrease in circulating regulatory T 
cell frequency may be associated with disease activity 139, as found by Crispin et al in SLE 25, 
but this is not consensual 134. 
Human CD4+CD25high T cells are anergic to in vitro stimulation and strongly suppress the 
proliferation of responder T cells upon culture 140. In vivo, the mechanisms involved in T reg 
mediated suppression remain to be determined. It is accepted that suppression by CD4+CD25+ 
T reg may be exerted by different means, depending on the microenvironment and on the 
pathologic context 18,141,142. Different AIDs may utilize different pathways to disease hence in 
some the dysfunction of CD4+CD25high regulatory cells may play a more prominent role 22 
that would possibly explain the heterogeneous results obtained in human diseases. The 
majority of research on CD4+CD25+ T cells has focused on their effects on T cell populations 
but they have also been shown to have some effects in B cell function. CD4+CD25+ T cells 
inhibited B cell proliferation induced by lipopolysaccharide in vitro 134 and prevented the 
activation of anti-DNA antibodies producing B cells in a transgenic system 143. Moreover, 
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activated CD4+ T helper cells presumably provide stimulatory signals to relevant self-reactive 
B cells, rescue them from apoptosis and stimulate them to form autoantibodies 144 and 
CD4+CD25+ may down-regulate this T cell mediated production of self-reactive antibodies in 
an adoptive transfer system 145.  
We hypothesized that CD4+CD25high deficiency could contribute to the documented high 
incidence of autoimmunity in CVID, either as a defect of a particular/ homogeneous group of 
patients or as a more universal CVID defect. Any genetic abnormality or environmental insult 
could favor the emergence of autoimmunity if it would tip the balance between T reg cells 
and self-reactive T cells toward the dominance of the later.  
In our population we found significantly lower CD4+CD25high frequencies in the group of 
CVID when compared to controls and in patients with AID when compared with those 
without AID. These results favor the hypothesis that impairment of CD4+CD25high is a 
common defect in CVID patients. The group of patients with AID had significantly lower 
CD4+CD25high frequencies suggesting this as one of the possible defects underlying their high 
susceptibility to autoimmunity.  
Other groups have investigated on CD4+CD25high both in animal and human studies and 
progresses in the area have revealed new aspects on their phenotype and function. 
Nevertheless, methodological differences across different studies, namely different staining 
and/or gating strategies and different depletion methods 22,146, may contribute to the 
heterogeneity in results concerning CD4+CD25+ frequency / function and turns their 
comparison into a difficult issue.  
Different methods for defining high intensity of CD25 expression may also influence 
CD4+CD25+ T reg quantification. Baecher-Allan et al initially defined CD4+CD25high as a tail 
to the right from the major population containing both CD4+CD25low and CD4+CD25-, as 
illustrated in their paper 34. We decided to adopt this definition, as Baecher-Allan et al 
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previously showed data supporting the suppressive ability towards co-cultured CD4+CD25- T 
cells of CD4+CD25high population obtained with their method 34. In order to minimize 
subjectivity in the present work, one single investigator performed all CD4+CD25+ cytometry 
evaluations, including acquisition and analysis, with no access to clinical data and applying 
the same uniform criteria to all patients.  
In our study, CD25high percentages within CD4+ T cells were highly variable both in patients 
and controls and there was a visible overlap between patients with and without AID and 
controls, although statistical evaluation found significant differences when comparing 
cohorts’ results. Baecher-Allan et al estimated CD4+CD25high in 1-2% of the total CD4+ 
population 34 and in our study, based on his method, CD4+CD25high mean percentage in 
healthy donors was 1.25 ± 0.36%, quite similar to data from other studies applying this 
methodology 27. 
Lately, other authors have defined CD4+CD25high T cells as those CD4+ T cells whose CD25 
positivity exceeded the level of CD25 positivity seen in the CD4- T cells 22, as those having 
intensity of fluorescence of CD25 expression exceeding 100 28,29,134,135, as the top 2% of the 
CD25 staining CD4+ T cells 28 or even do not state the method that has been used for defining 
high expression of CD25 20,25,26. Moreover, CD25high frequencies are variably expressed 
within CD4+ or lymphocyte gate in different studies 22 and, again, some authors do not state 
which percentage is used 32. Finally, some authors report on CD4+CD25+ T reg frequency 
without expressing if they are referring to CD25high expression or to all CD25 positive T cells 
18. Whole CD4+CD25+ contain a relatively high proportion of previously activated T cells, 
rather than naturally occurring CD4+CD25high T reg cells, as CD25 is transiently up regulated 
on non-regulatory CD4+ T cells upon activation and does not confer suppressive activity by 
itself. Therefore not all CD4+CD25+ cells are considered to be regulatory T cells. 
 
 
61
Susana Lopes da Silva 
CD4+CD25high population includes the majority of cells with demonstrated suppressive 
capacity 34.  
CD4+CD25+ T reg are believed to be in late stage of differentiation and are mainly found 
within the CD4+CD45RA-/RO+ T cells, thus displaying a memory T cell phenotype 34. 
Concordantly, in our study CD4+CD25high T cells were mostly CD45RO+, both in CVID 
patients with and without AID and in controls. The only activation marker that was evaluated 
in our population was HLA-DR expression. We found no significant differences in absolute 
number / percentages of HLA-DR+ cells within CD4+ or CD8+ T lymphocytes between 
patients with and without AID and there was no correlation between CD4+CD25highCD45RO+ 
frequencies and those subsets, further supporting that CD4+CD25high differences between 
groups were not directly dependent on immunologic activation. 
Other markers have been linked to CD4+CD25+ T reg, including CD152 (Cytotoxic T 
Lymphocyte associated-Antigen 4 - CTLA-4) 147, Glucocorticoid-Induced TNF-Receptor 
family-related gene (GITR) 148,149, CD62 L150 and the Forkhead transcription factor (FoxP3) 
151, 152,153,154. 
FoxP3 was recently reported to be essential for the development and suppressive activity both 
in mice and human CD25+ T reg cells 34,155,156 and it controls CD25 expression in natural T 
reg cells but not in activated T cells in general 151. FoxP3 quantitative expression was 
correlated with functional suppression in the peripheral CD4+CD25+ T cell compartment in 
multiple sclerosis patients 157. FoxP3 mutations underlie a fatal autoimmune 
lymphoproliferative disorder in humans, termed immune dysregulation polyendocrinopathy 
enteropathy X-linked (IPEX) Syndrome 158,159. Considering that the development of natural T 
reg cells is at least in part genetically programmed, it has been suggested that autoimmunity 
might be considered in part as a primary T cell deficiency 19, eventually another way to close 
the circle between immunodeficiency and autoimmunity.  
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The use of additional markers that allow a more detailed quantification, like FoxP3, might 
improve the evaluation of the role of CD4+CD25+ T reg in CVID and AID. After we 
presented our preliminary results 160, Horn et al have presented data on FoxP3+CD25high 
regulatory T cells quantification in 48 patients with CVID 161. In this study, no significant 
differences were found in patients as compared to healthy controls. Although patients were 
not divided according to AID diagnosis, the authors reported that only one patient out of 17 
with AID, presented T reg frequency below the 5th percentile. Both differences in 
populations’ demographic or clinical characteristics and in lab methods used may have 
contributed to this disparity in results between these two studies.  
Even though no other markers were used in our study, some authors have considered high 
expression of CD25 as a good marker for natural CD4 T reg 19,154, when cautiously analyzed. 
In addition, the differences we found in CD4+CD25high frequencies between patients with 
AIDs and both controls and patients with no AID were clearly significant and, notably, these 
differences in CD4+CD25high maintained statistical significance after exclusion of the two 
patients under treatment with cyclosporine. This analysis was performed because there is 
limited data available on how calcineurin inhibitors influence regulatory cells development 
and function in vivo 162. 
 
Defective thymopoiesis in CVID, previously mentioned 95,96, may contribute to the low 
percentages of CD4+CD25high T reg, as thymus is a primary source of a subpopulation of these 
CD4+CD25+ T reg cells 163. Nevertheless, mechanisms regulating this production remain 
unclear 18 and in a study involving myasthenia gravis patients, thymectomy showed no 
obvious influence on the frequency of CD4+CD25high 20. 
Molecular defects underlying immunodeficiency may interfere with the establishment or 
maintenance of self-tolerance by interference with expression of cytokines such as IL2, whose 
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deficiency has been reported in CVID and which is important in both triggering the apoptosis 
of auto-reactive T cells 40 and in the maintenance of CD4+CD25+ T reg in the periphery 19. 
Although CD4+CD25+ T reg typically do not produce IL2, they depend on this cytokine 
signaling for development in the thymus, expansion in the periphery and activation of their 
immunosuppressive function 164,165,166. Inhibition of IL2 production, for example by 
cyclosporine, may reduce natural T reg cells in the periphery by affecting their survival 19,21 
and in vivo neutralization of IL2 reduces the peripheral and thymic frequency of T reg but not 
other T cells and causes AID in mice 167. 
IL2 deficiency in CVID has been interpreted as a result of lymphopenia 112,117, which 
curiously has been described in association with CD4+CD25high expansion in different 
contexts 35. Regulatory cells are thought to play a protective role in situations where 
lymphopenia driven proliferation generates autoimmune clones selectively controlling their 
expansion and type of response 168. 
In our population we did not find lymphopenia or significant differences between lymphocyte 
percentages or absolute counts between patients with and without AID. Moreover, we found 
no correlation between lymphocyte counts and CD4+CD25high, both when considering all 
patients or dividing them according to clinical history of AIDs. Evaluation of T cell ability to 
produce IL2 would be interesting in this context. 
Correlations between low CD4+CD25+ T regulatory cells and impaired IL12 production 25 and 
data reporting that CD80 and CD86 expression in dendritic cells influence on CD4+CD25+ T 
reg mediated suppression 169 may also suggest a possible interference of other previously 
mentioned CVID immunological defects in CD4+CD25+ frequency and / or function 25,169. 
Age-dependent variances in CD4+CD25high frequency or function have been reported 135. 
Gregg et al reported a progressive increase in CD4CD25high cells proportion with age, which 
was interpreted as predominantly derived from peripheral expansion, without significant 
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difference in suppressive efficiency 170. On the other hand, Tsaknaridis et al found a decline in 
suppressive activity of CD4+CD25+ T cells with age and hypothesized that this could be 
influenced by age dependent decline in thymic function 171. Taking into account that 
significant differences were found between patients with and without AID both in age and 
CD4+CD25high percentages, it would be relevant to exclude the age contribution to this result. 
In our population, as occurred with others 28,29, we found no correlation between age and 
CD4+CD25high frequency when evaluating the whole group of patients and controls. Control 
and CVID cohorts have been age - matched, which further argues against age as a relevant 
factor to explain lower CD4+CD25high frequencies in patients. Interestingly, we found that 
within the subset of patients with AID, CD4+CD25high frequency increased with age. 
Tsaknaridis hypothesis may not be excluded by our study, as suppressive activity was not 
evaluated.  
Relationship between CD4+CD25high frequencies and other clinical characteristics besides 
autoimmunity were also investigated and a significant difference was found when comparing 
CD25high proportion within CD4+ T cells between patients with and without chronic non-
infectious diarrhea. In other studies, CD4+CD25high T cells were decreased in the peripheral 
blood of patients with active inflammatory bowel disease 172 but significantly increased in 
intestinal lamina propria although retaining similar regulatory activity when compared with 
those from normal individuals 138. 
WE found no significant differences in CD4+CD25high T cells frequencies when dividing 
patients according to the presence of bronchiectasis, splenomegaly, lymphoid proliferation or 
granulomas.  
 
Some studies have been designed in order to establish a classification of CVID patients that 
allows predicting those who will develop AIDs, which so far has not been achieved 16. We 
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propose CD4+CD25high deficiency as a marker to identify those patients with increased risk 
for autoimmunity, although deficiency or dysfunction of natural T reg cells per se cannot 
determine which organs or tissues are to be targeted by the triggered autoimmune responses 
126. Considering the important overlap that we observed in CD4+CD25high frequencies both 
between patients with and without AID and between patients and controls, we should 
probably look at the prognostic value of longitudinal individual values, instead of determining 
strict cut-offs.  
Additional therapeutic strategies may be used in selected patients in association with IVIG 
replacement 173. In patients with AID and CD4+CD25high deficiency, the reestablishment or 
newly establishment of dominant tolerance could be tried, either by helping naturally present 
T reg cells to expand, strengthening their suppressive activity or by induction of adaptative T 
reg 18,174,175. CD4+CD25high cells were effectively expanded in vitro in presence of high 
concentrations of exogenous IL2 while retaining their suppressive activity 175. 
Initial trials with only few patients using synthetic 177,178,179 or natural human IL2 180 showed 
some potential clinical benefit, although further work is needed, with longer and larger studies 
and more clinical endpoints, particularly concerning AIDs. In vitro and in vivo treatment with 
steroids was found to up regulate FoxP3 expression in CD4+ lymphocytes of healthy donors 
and in asthmatic patients 176 and has been noted to promote T reg cell development and 
function. 
These alternative therapeutic strategies require further data before considering translation of 
these studies to the clinical practice.   
 
In summary, in our population, patients with CVID presented mean CD4+CD25high 
frequencies lower than healthy controls and this difference was more pronounced in the 
subpopulation of patients with AID. This may be one more piece to join the many pieces that 
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have been collected from the complex puzzle of CVID. It is not clear which of the T and B 
cell abnormalities are possibly causative, which are secondary and which are only 
epiphenomena. Moreover, some of the abnormalities have been detected in subpopulations of 
patients and do not constitute a universal defect in CVID patients. 
Our results should prompt us to more detailed phenotype and functional evaluation of 
CD4+CD25high T cells, involving larger cohorts, in order to confirm and integrate our findings 
and obtain a deeper perspective on their role in CVID and AID.  
Unquestionably, retrospective methodology has limited our clinical characterization and 
perception of AIDs evolution in this group, therefore demanding further follow-up studies 
with clinical and immunologic data simultaneous collection. Longitudinal studies will also be 
instrumental to clarify the prognostic value of CD4+CD25high allowing us to offer each patient 
optimal and individually adapted follow-up and treatment protocols. 
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Table 1: Patients with autoimmune diseases - diagnosis, age at presentation and treatment.  
 
Case 
Number Gender/age AID (age at presentation) AID treatment 
1 M / 44 AIHA (29);ITP (39); alopecia areata (30) AIHA: OS; ITP: splenectomy, AZT, Cy; alopecia areata: topical steroids  
2 F / 61 Rheumathoid Arthritis (40) NSAIDs 
3 F / 63 ITP (58)   
4 M / 42 Pernicious anemia (39) Intramuscular vitamin B12 
5 M / 71 Sjogren's Syndrome (60)   
6 M / 21 Crohn's disease (21); eritroblastopenia (20) Cy + OS 
7 M / 63 Pernicious anemia (60) Oral cyanocobalamin  
8 M / 34 Psoriasis (22)   
9 F / 54 Pernicious anemia (44) Intramuscular vitamin B12  
10 F / 45 Pernicious anemia (39) Intramuscular vitamin B12 
11 F / 44 Psoriasis (30) Topical treatment 
12 M / 40 Alopecia areata (29), hypothyroidism (7) Topical steroids, Levothyroxine  
13 F / 42 ITP (13), Crohn's disease (38) ITP: OS, splenectomy. CD: OS, mesalazine, Cy 
14 F / 30 Rheumathoid Arthritis (30) OS, NSAIDs 
15 F / 16 Evans´s Syndrome (AIHA, ITP) (10) OS 
16 M / 58 ITP (30) OS 
17 F / 25 Vitiligo; autoimmune hepatitis (9) OS, AZT 
18 M / 53 Alopecia areata, ITP (46) OS 
19 F / 55 Rheumathoid Arthritis (25) OS, hydroxychloroquine 
 
NOTE: AIHA, autoimmune hemolytic anemia; AZT, Azathioprine; CD, Crohn´s disease; Cy, cyclosporine; F, female; ITP, immune trombocytopenic purpura;  
M, male; NSAIDs, non-steroidal anti-inflammatory drugs; OS: oral steroids. 
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Table 2: Clinical profile of patients with AID 
Case 
Number 
Age at 1st
symptoms / type
Age at 
diagnosis / 
beginning 
IVIG 
Respiratory 
infections Bronchiectasis Chronic diarrhea LH Granulomas Other clinical manifestations 
IVIG 
(mg/Kg/month) 
1 17 / RI 32 / 34 U+L Yes Giardiasis + NLH + intestinal amyloidosis A Yes* No CMV adenitis  1360 
2 7 / RI 58 / 58 U+L Yes Non- infectious  No No Frequent Herpes I infections, sepsis  513 
3 40 / RI 58 / 59 U+L Yes Non- infectious No No Frequent Herpes zoster infections (5x) 450 
4 14 / RI 34 / 34 U+L Yes Infectious  Non-infectious   Yes Yes  640 
5 51 / RI 58 / 59 U+L Yes Non- infectious / NLH Yes Yes  453 
6 4 / RI 13 / 14 U+L Yes Infectious  Non-infectious Yes No Frequent Herpes I infections 667 
7 25 / RI 57/ 59 U+L Yes Non- infectious / NLH Yes No Acute colangitis - E coli, duodenal papilla cyst 594 
8 6 / RI 24 / 24 U+L Yes Giardiasis  Non-infectious Yes No   373 
9 7 / RI 32 / 40 U+L Yes No Yes n.a.   n.a. 
10 34 / RI 39 / 39 U+L Yes Infectious  Non-infectious No No   784 
11 25 / RI 41 / 41 U+L Yes No No No Ferropenic anemia, sepsis (Klebsiella), duodenal ulcer 520 
12 7 / AID 36 / 37 U+L Yes Infectious  Non-infectious Yes No Chronic prostatitis, hepatitis  480 
13 13 / AID 30 / 30 U+L Yes Infectious Non-infectious Yes* Yes 
Sepsis (Morganella morganii), frequent conjunctivitis,  
intestinal CMV 1820 
14 30 / AID 49 / 50 U+L Yes No Yes No   380 
15 10 / AID 12 / 12 L Yes Non-infectious / NLH Yes n.a.   n.a. 
16 30 / AID 54 / 54 No No No No n.a.   n.a. 
17 9 / AID 14 / 14 No No No No No   625 
18 46 / AID 52 / 52 No No No yes n.a.   n.a. 
19 25 / AID 36 / 36 U+L Yes Infectious diarrhea  No No Frequent cutaneous mycosis 373 
NOTE: AID, Autoimmune diseases; CMV, Cytomegalovirus; IVIG intravenous immunoglobulin; L, lower respiratory tract; LH, lymphoid hyperplasia; NLH, nodular lymphoid hyperplasia; RI, 
respiratory infections; U, upper respiratory tract; n.a.; data not available; * status post splenectomy 
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Table 3: Immunological profile of patients with AID 
 
Immunoglobulin levels at diagnosis Cross-sectional evaluation 
IgG  IgA IgM  IgG1  IgG2  IgG3 Last IgG WBC Lym  CD3 CD4
CD4 
counts CD4/CD8 CD8 CD19 NK 
HLA-DR+ 
within CD4 
HLA-DR+ 
within CD8 Hb Platelets 
Case 
number 
mg/dL Mg/dL mg/dL mg/dL mg/dL mg/dL mg/dL cells /μL cells /μL % % cells /μL  % % % % % g/dL cells /μL 
1 500 45 116 560 116 90 538 7500 3100 70 33 1023 1.2 28 17 11 19 43 13 103 
2 466 30 50 419 59 21 894 5100 900 74 55 495 2.9 19 19 6 7 17 12 181 
3 217 <7 9 209 23 5 992 3300 800 70 37 296 1.3 28 21 8 20 28 12,4 77 
4 160 <7 17 168 11 <5 863 5800 1500 85 43 645 1.1 38 5 9 20 51 14.3 199 
5 574 10 33 480 8 80 n.a. 6100 1300 n.a. 26 338 n.a. n.a. 8 13 n.a. n.a. n.a. n.a. 
6 567 6 10 n.a. n.a. n.a. 604 7400 1400 77 19 266 0.4 49 3 18 n.a. n.a. 12.3 227 
7 174 <7 6 110 38 <5 451 10000 1800 n.a. 50 900 n.a. n.a. 5.8 7 n.a. n.a. n.a. n.a. 
8 320 7 6 200 120 24 687 7700 1600 89 48 768 1.3 37 4 5 3 9 14.5 208 
9 98 84 39 n.a. n.a. n.a. 591 3270 1242 82 35 434.7 0.8 45 7 10 36 81 13.0 103 
10 389 <7 90 151 96 <5 413 9100 2000 76 44 880 1.5 29 11 10 4 6 8.9 509 
11 445 71 191 381 10 22 903 6400 1600 71 43 688 1.8 24 11 16 3 5 12.3 292 
12 549 <7 56 413 33 162 846 5500 1000 66 45 450 2.4 19 12 20 10 25 13.5 209 
13 313 <10 42 200 60 8 578 11200 4100 61 21 861 0.5 39 3 33 45 71 8.3 547 
14 385 <10 54 252 37 8 972 4700 900 71 31 279 0.8 38 15 13 16 32 13 260 
15 505 35 62 288 52 95 660 11400 3300 82 64 2112 3.6 18 14 3 17 11 14.3 327 
16 300 25 25 n.a. n.a. n.a. 542 5650 1510 80 48 724.8 1.5 32 8 12 37 52 15 186 
17 438 <7 64 348 <5 12 610 9300 2900 80 39 1131 1.0 38 15 4 12 14 13.2 186 
18 374 30 35 281 83 5 687 4120 1210 72 49 592.9 2.0 24 14 7 21 33 15 145 
19 440 11 15 n.a. n.a. n.a. 913 2700 1000 NA 42 420 0.8 51 2 3 18 44 12.2 119 
 
NOTE: n.a.; data not available 
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Table 4: Comparison of clinical and laboratory data between patients with and without AID 
 
 
 
 
All patients 
(n=47) 
AID No AID 
(n=28) 
AID vs. no AID 
(p value) (n=19) 
25/22 9/10 16/12 > 0.05 Gender (M/F) 
Age (years) 37.7 ± 16.0 46.5 ± 15.0 31.8 ± 14.0 0.0017 
15.6 ± 14.7 21,0 ± 14,4 13.5 ± 13.4 > 0.05 Age at first symptoms (years) 
Age at diagnosis (years) 28.4 ± 17.6 38.2 ± 16.0 22.7 ± 15.7 0.0022 
30.0 ± 16.7 39.0 ± 16.1 24.6 ± 15.4 0.004 Age at beginning treatment (years) 
Time 1st symptoms – diagnosis (years) 12.8 ± 12.4 17.1 ± 12.0 9.1 ± 9.7 0.022 
14.3 ± 12.7 18.0 ± 12.6 11.1 ± 9.9 0.05 Time 1st symptoms – treatment (years) 
43 (91.5%) 16 (84.2%) 27 (96.4%) > 0.05 Bronchiectasis (n)  
19 (40.4%) 12 (63.15%) 7 (33.3%) 0.015 Chronic non infectious diarrhea (n) 
22 (46.8%) 9 (47.4%) 13 (46.4%) > 0.05 Chronic infectious diarrhea (n) 
14 / 45 (31.1%) 8 / 17 (47.1%) 6 (21.4%) > 0.05 Splenomegaly (n) 
21 (44.7%) 12 (63.2%) 9 (32.2%) 0.043 Lymphoid hyperplasia (n) 
3 (6.4%) 3 (15.8%) 0 (0%) > 0.05 Granulomatous disease (n) 
618.2 ± 511.3 668.9 ± 401.7 586.5 ± 575.4 > 0.05 IVIG doses (mg/kg/month) 
294.5 ± 147.3 379.7 ± 141.7 234.5 ± 120.8 0.0009 IgG at diagnosis (mg/dL) 
22.5 ± 29.8 24.2 ± 26.8 21.3 ± 32.3 > 0.05 IgA at diagnosis (mg/dL) 
43.8 ± 52.4 50.7 ± 46.5 38.8 ± 56.6 > 0.05 IgM at diagnosis (mg/dL) 
227.2 ± 126.1 297.3 ± 131.6 181.4 ± 100.8 0.0078 IgG1 at diagnosis (mg/dL) 
50.3 ± 54.9 50.1 ± 38.6 50.5 ± 64.2 > 0.05 IgG2 at diagnosis (mg/dL) 
26.9 ± 34.2 36.5 ± 47.6 20.4 ± 19.6 > 0.05 IgG3 at diagnosis (mg/dL) 
658.1 ± 147.4 695.9 ± 181.5 633.3 ± 117.4 > 0.05 Last IgG (mg/dL) 
6740 ± 2514 6644 ± 2626 6804 ± 2481 > 0.05 Leucocytes (cells /μL) 
1954 ± 1304 1745 ± 932.3 2096 ± 1505 > 0.05 Lymphocytes (cells /μL) 
76.3 ± 7.4 75.4 ± 7.4 76.8 ± 7.4 > 0.05 CD3 (%) 
1529 ± 1091 1360 ± 700,9 1626 ± 1263 > 0.05 CD3 counts (cells /μL) 
41.0 ± 11.4 40.6 ± 11.4 41.3 ± 11.1 > 0.05 CD4 (%) 
759.3 ± 392.8 700.2 ± 429.2 799.4 ± 368.7 > 0.05 CD4 counts (cells /μL) 
1.5 ± 0.8 1.5 ± 0.8 1.5 ± 0.8 > 0.05 CD4/CD8 
32.5 ± 11.7 32.7 ± 10.3 32.4 ± 12.6 > 0.05 CD8 (%) 
11.0 ± 4.9 10.2 ± 5.8 11.5 ± 4.3 > 0.05 CD19 (%) 
217.6 ± 175.7 174.9 ± 143.0 246.5 ± 191.9 > 0.05 CD19 counts (cells /μL) 
10.1 ± 6.5 11.0 ± 7.2 9.5 ± 6.0 > 0.05 NK (%) 
16.7 ± 12.8 18.0±12.4 15.7±13.3 > 0.05 HLA-DR + cells within CD4+ (%) 
28.1 ± 19.6 32.6 ± 23.0 24.7 ± 16.2 > 0.05 HLA-DR + cells within CD8+ (%) 
13.1 ± 1.7 12.8 ± 1.8 13.4 ± 1.6 > 0.05 Hb (g/dL) 
Platelets (cells /μL) 219.0 ± 91.7 228.1 ± 131.3 213.3 ± 56.6 > 0.05 
 
NOTE: 1 - Data are presented as mean ± SD, unless indicated otherwise; 2 - IgA level was below the cut-off of the test in 
10/19 patients; cut-off value (7mg/dL) was therefore used to calculate the mean and SD. IVIG, intravenous immunoglobulin. 
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Table 5: CD4+CD25+ quantification 
 All patients CVID (n=47) 
AID No AID 
(n=28) 
Controls 
(n=29) (n=19) 
25 / 22 9 / 10 16 / 12 13 / 16 Gender (M/F) 
37.7 ± 16.0 46.5 ± 15.0 †† 31.8 ± 14.0 §§ ** 40.8 ± 9.5 ††Age 
CD4+CD25+ 16.8 ± 6.7 14.2 ± 4.4 * † 18.4 ± 7.5 § 17.1 ± 4.8 §
CD4+CD25high 0.96 ± 0.63 * 0.65 ± 0.37 *** †† 1.17 ± 0.69 §§ 1.25 ± 0.36 # §§§
CD4+CD25highRO+ 96.1 ± 4.3 96.6 ± 5.4 95.8 ± 3.4 96.52 ± 2.75 
 
NOTE: Data are presented as mean ± SD 
CD4+ CD25+ - percentage of CD25+ cells within CD4+ T cells  
CD4+ CD25high - percentage of CD25high within CD4+ T cells 
CD4+ CD25highRO+ - percentage of CD45RO+ cells within CD4+ CD25high T cells 
# Significance in comparison with all patients with CVID: ### p<0.001; ## p<0.01; # p<0.05 
§ Significance in comparison with patients with AID: §§§ p<0.001; §§ p<0.01; § p<0.05 
† Significance in comparison with patients with no AID: ††† p<0.001; †† p<0.01; † p<0.05 
* Significance in comparison with controls: *** p<0.001; ** p<0.01; * p<0.05 
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 Figure 1  
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Figure 1 – Flow cytometry  
CD4+CD25high were quantified in whole blood on a Fluorescense Activated Cell Sorter 
FACSCalibur (Becton-Dickinson®). We show dot plot of a healthy control illustrating 
CD4+CD25high definition adopted in this work based on Baecher-Allan et al 34, in which 
CD4+CD25high cells appear as a tail to the right from the major population containing both 
CD4+CD25low and CD4+CD25- cells. 
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Figure 2 
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Figure 2 - Age distribution of the cohorts  
 
Age distribution of healthy controls and CVID patients with and without AID. Each dot 
represents one individual. Bars represent means. Statistical significance between groups:  
* p<0.05; ** p<0.01; *** p< 0.001. 
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Figure 3 
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Figure 3 – Analysis of the expression of CD25 within CD4+ T cells. 
Patients with CVID and healthy controls were evaluated for CD25 expression within CD4+ T 
cells by flow cytometric analysis of the intensity of fluorescence: (A) Proportion of CD4+ T 
cells that express CD25 and (B) Proportion of CD4+ T cells that express high intensity of 
CD25 fluorescence. For comparison between patients with and without AID, results are 
shown in different columns. Each dot represents one individual. Bars represent means. 
Statistical significance between groups: * p<0.05; ** p<0.01; *** p< 0.001. 
 
  108 
Autoimunidade e células reguladoras T CD4+CD25High na Imunodeficiência Comum Variável 
 
Figure 4 
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Figure 4 – Analysis of the correlation between age and CD4+CD25high in patients with 
CVID and AID.  
Graph illustrating the positive correlation between age and proportion of CD4+CD25high 
within CD4+ T cells. No significant correlation was found between these two variables when 
analyzing controls or patients without AID. 
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